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ABSTRACT
Adenovirus-mediated expression of a modified simian rotavirus capsid protein
(SA-11 VP7sc) in 293 cells has been demonstrated. Based on this observation and due
to the high-level similarity between VP7 proteins from different rotavirus serotypes,
VP7sc from the Wa strain (serotype Gl) was rescued into the adenovirus (Ad5) El
region to obtain its expression following infection of 293 cell This gene which has
been constructed and expressed in COS cells, was prepared from pJCWaVPTsc
plasmid. The gene was first subcloned into Bluescript to facilitate selection of
recombinants following ligation of the CMV promoter DNA upstream of it. This
cassette was then subcloned into the polycloning site of pXCX3, a plasmid containing
16% left-hand sequences of Ad5. This step produced pXCVPV Plasmid which could
give rise to the rescue of WaVP7 in the El region of Ad5 following cotransfection and
homologous recombination with pJMlT, a plasmid containing aknost the entire genome
of Ad5.
Recombinant adenovirus plaques were analysed by restriction digestion of viral
DNA and shown to have the expected structure. Protein expression was then examined
at 18 and 24hrs post-infection by methionine radiolabelling and immunoprecipitation of
the protein. Despite the successful rescue of the gene into Ad5 genome, expression of
the relevant protein was not achieved. However, a control protein from another virus
was expressed. To explore the source of this problem, two strategies were adopted:
PCR-mediated detection of WaVP7sc gene in recombinant virus and sequencing of the
CMV promoter DNA. The former showed the existence of the gene in the viral genome
DNA. The latter revealed two point mutations. These mutations may have been
introduced by the Taq DNA polymerase during PCR amplification of the promoter.
Since one of the mutations occurred in a repeated sequence near the TATA box, the
failure of 293 cells to express WaVPVsc protein might have been due to this mutation.
If construction of the CMV WaVPTsc were to be repeated, substitution of SA-11 VP7sc

by WaVP7sc in the plasmici successfully used for expression of SA-11 VP7sc protein
would be an immediate solution to the problem.
Expression of WaVPTsc protein is part of a strategy to develop a rotavirus
vaccine based on recombinant DNA techniques. This recombinant virus would have
been one component of a multivalent vaccine.
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Section i: General Characteristics of Rotaviruses
Ll> Disease:
Rotaviruses, a member of the Reoviridae family, are 70-nm in diameter, non-enveloped
particles initially described in duodenal biopsies from young children hospitalised with acute
gastroenteritis (18). They are recognised as the major etiologic agents of severe gastroenteritis
among infants and young children in most regions of the world. The study of biopsies of the
jejunum of the infants hospitalised with rotavirus infection has revealed a number of pathogenic
effects of these viruses. These effects include shortening and atrophy of the vilH, mononuclear
cell filtration in the lamina propria, distended cisternae of the endoplasmic reticulum,
mitochondrial swelling, and sparse, irregular microvilli (84). Columnar epithelial cells, goblet
cells and phagocytes in the lamina propria were the main cell types in which rotavirus particles
were visualised.
As a result of severe pathological feamres of rotaviruses exemplified above, diarrhoeal
diseases caused by these viruses are responsible for a large proportion of deaths especially in
developing countries. For instance, in 1977-1978, there were 3 to 5 billion cases of diarrhoea
and 5 to 10 million deaths associated with diarrhoea in these areas. Although the cases of the
disease decreased to 14 million in 1986, the high proportion of diarrhoeal death, 873000
(mainly among children) (145) demonstrated a need for treatment of the disease.

1.2. Morphology:
Based on their morphologic appearance, three types of rotaviral particles (doubleshelled, single-shelled, and core) have been defined (24a, 86). Complete particles have a
double-layered capsid and are designated "smooth" particles as the outermost margin of the
outer capsid layer has a smooth, circular appearance. Single-shelled particles have a rough
periphery due to the projecting subunits of the inner capsid. These are transcriptionally active.
Inside the single-shelled particle is a core which contains genomic RNA but does not have
transcriptional activity.

1.3. Rotavirus Genome:
The rotavirus genome contains 11 segments of double-stranded RNA ranging in
molecular weight (MW) from 2 x 10^ to 2.2 x 10^ Daltons (49, 94, 95, 146). In each genomic
segment, a 5'-guanidine followed by 5'-noncoding conserved sequences is present. An openreading frame coding for the protein product is then found which ends with the stop codon.
Each RNA segment also has 3' noncoding sequences which include conserved terminal
sequences and which end with a 3'-terminal cytidine. The terminal sequence conservation
suggest that the sequences may contain signals essential for transcription, replication, or
assembly of viral genome structures.

1.4. Rotavirus Proteins: Structure & Function
Proteins encoded by rotavirus genome fragments are divided into structural proteins
found in virus particles and nonstructural proteins found in infected cells but not present in
mature viral particles. Structural proteins are designated viral protein (VP) followed by a
number, with VPl being the highest-molecular-weight protein.

VPl (47), VP2 (16) and VPS (103) encoded by gene segments 1, 2 and 3, respectively,
are components of the rotavirus central core. VPl is also suggested to participate in the
structure of the viral RNA polymerase (58). VP2 is probably the only protein in the central core
which shows RNA binding activity, although it is not sequence-specific (23). The VP3 protein
is suggested to contribute to RNA synthesis and replication (55). Gene segment 6 encodes
VP6, a protein which functions both as an antigen (74) and as a ligand during early stages of
rotavirus morphogenesis (6, 117). NS26 is an 0-linked glycosylated, phosphorylated protein
encoded by gene segment 11 (60, 189). In addition to the NS26 protein, a second protein
called NS12 has been described which is produced from an out-of-frame open reading frame of
gene 11 (112).
Little is known about the precise functions of non-structural proteins NS53, NS34 and
NS35. However, an RNA binding activity has been suggested for NS53 (47), a protein
encoded by gene segment 5 (46). Proteins NS34 encoded by gene segment 7 of SAll (43),
and NS35 encoded by segment 8 (132) may participate in viral replication (130, 140), but their
roles have not been exactly determined.
Three of the rotavirus proteins (VP4, VP7 and non-structural NS28) have been studied
extensively because of their unique biochemical and biological functions in viral replication.
VP4 is a non-glycosylated outer capsid protein produced by genome segment 4 (5, 109). The
proteolytic cleavage of VP4 results in an increase in viral infectivity probably by increasing
penetration of virus into cells (29, 53, 96). Furthermore, monoclonal antibodies to rhesus
rotavirus with ability to inhibit haemaglutinin have immunoprecipitated VP4 (76), indicating
that VP4 is a viral haemaglutinin. The protein can also induce protective immunity in animals
and is immunogenic in children and animals (31,173).

Cryo-electron microscopy of virus surface shows that VP4 appears as projections or
spikes on the surface extending between 100 and 120 A (135, 135a). The surface projections
function in both cell attachment and haemaglutination (54, 100, 110).
The primary product of gene 10 is non-structural protein NS28 with a molecular weight
of 20kD. It is glycosylated and undergoes subsequent oligosaccharide processing to the mature
28-kD transmembrane protein of the ER (46, 92). Although the amino terminus of NS28
remains in the ER membrane, the carboxy terminus, with its hydrophilic nature, extends into
the cytoplasm of infected cells. This cytoplasmic domain probably acts as a receptor to bind
subviral particles and directs their budding into the lumen of the ER during virus assembly (6,
12, 117).
VP7, as an outer capsid protein encoded by gene segment 9 (21), is the second most
abundant protein species in the virion. Its co-translational glycosylation takes place as it is
inserted into the membrane of the ER. This glycoprotein contains only N-linked high-mannose
oligosaccharides which are processed by trimming (93). Indeed, the ER is the exclusive site of
VP7 production and processing, as rotavirus particles are not transported to the Golgi
apparatus. In addition to its essential role as the rotavirus major antigen (See Section 1.6.
Serotype Antigens of Rotaviruses), VP7 probably mediates the attachment of virus to host
cells.
1.5. Rotavirus Replication:
Studies on different cell lines susceptible to rotavirus infection have revealed important
characteristics of replication of these viruses. Double-shelled particles are the only infectious
forms of rotavirus (132). Studies with SA-11 double-shelled rotaviruses have shown that these
particles attach to cells via sialic acid carried on an unidentified cellular receptor (10).

VP7 seems to have a role in the process and appropriate conditions including the
presence of sialic acid (10, 194) and sodium (132) are required for viruses to bind cells. Virus
intemalisation occurs by 60-90 minutes after binding by one of two mechanisms. Early studies
with the S A l l isolate, for instance, show that it is probably endocytosed and rapidly
transported to lysosomes (132, 138). However, subsequent studies with a trypsin-pretreated
human rotavirus suggest direct penetration of viral particles through the cell membrane into the
cell cytoplasm (170). Also, direct release of nucleic acid following activation of the virus by
trypsin has been observed (170). Direct entrance of the virus into the cell may increase
productive infection. In fact, trypsin-treated rhesus rotavirus enters MA 104 cells more quickly
via direct penetration than non-treated vims which is taken up via endocytosis (96).
Rotavirus infection in tissue culture has also been shown not to be reduced by inhibitors
of endocytosis. Furthermore, energy inhibitors have a minimal effect on its infectivity (96).
These observations further suggest that direct cell membrane penetration is the only pathway by
which an infectious rotavirus enters cells.
A viral RNA-dependent RNA polymerase present in the particle mediates the synthesis
of viral transcripts. Since this transcriptase is latent in double-shelled particles, it is thought that
uncoating of single-shelled particles activates transcription of mRNAs in infected cells.
Transcription is asymmetric and all transcripts are full-length positive strands produced from
the negative RNA strand (113).
Ribosomes in viroplasms are the sites where the majority of rotavirus structural proteins
and all non-structural proteins are produced. However, the glycoproteins VP7 and NS28 are
synthesised on the ER membrane-associated ribosomes and inserted into the ER membrane due
to signal peptides at their amino termini (92, 93).

Two pathways by which rotaviruses assemble through the ER membrane have been
described by electron microscopy evidence. One is called the enveloped particle pathway and
mainly includes single-shelled particles. These particles are temporarily enveloped by budding
from the cytoplasm into the ER lumen. The subsequent rupture of the envelope results in the
release of particles in their single-shelled form during cell lysis (169, 133). The enveloped
particles, however, seem to result from inefficient virus maturation, as an alternative pathway
has been observed for double-shelled particle formation (171). Again, single-shelled particles
are suggested to be involved in this second pathway in which they selectively acquire
components of the virus outer capsid during their movement through the ER membrane.
Although the majority of double-shelled particles have been reported to remain attached to the
cellular membranes and cytoskeleton even after cytolysis (122), they are released from the cell
in the last step of this newly-explained pathway (171).
Neutralising monoclonal antibodies can distinguish between VP7 on intact viral
particles and unassembled VP7 which is associated with the ER membrane. Kinetic analyses of
the processing of the oligosaccharides on the two pools of VP7 have shown that the
membrane-associated VP7 functions as the precursor to virion VP7 (92).
Calcium seems to be essential for rotavirus maturation. Reduced amounts of virus
yields (157b), loss of budding of virus particles and decreased levels of VP7 production (157a)
have been observed in calcium-free medium. Reduction in VP7 levels is suggested to be due to
preferential degradation of the molecule. Therefore, calcium seems to play a role in stabilising
the folding of newly synthesised VP7 molecules.
Virus particles are released by host-cell lysis. However, as mentioned above, many
single- and double-shelled particles remain associated with cell debris (122), suggesting that
these particles interact with intracellular structures. The detailed function of these interactions

and especially the possible role of cytoskeleton in transporting viral components remain to be
determined.
1.6. Serotype Antigens of Rotaviruses:
Vp4. This protein functions independently from VP7 as protective antigen in vivo . This has
been shown by a study in which infection of infant piglets with a reassortant virus bearing the
VP4 of one of its virulent parents and the VP7 of the other parent induced resistance to disease
caused by either virulent parental virus (88). The stimulation of equal levels of antibodies by
either antigen in this case study demonstrated a significant role for VP4 in protective immunity.
Although initial identification of human rotavirus (HRV) serotypes (G serotypes) is
based on the VP7 glycoprotein (11, 159), a new serotyping system has also been introduced
which includes VP4 as a serotype (P serotypes) antigen (62). Sequence analysis has revealed at
least 4 alleles of the VP4 gene among HRVs (61, 123, 176). Separate expression of 3 VP4
alleles

by using baculovirus vectors and subsequent immunisation with the yielded

recombinant proteins has defined the extent and distribution of VP4 antigenic polymorphism
among HRVs (62). The P-serotype system may be comparable or even, in some cases, more
reliable than the G-serotype system. For instance, only one Wa serotype has been identified by
each system. Another example is the murine rotavirus strain Eh in which the P-serotype system
of classification has been able to distinguish between 10 different serotypes compared to 3
serotypes identified by the G-serotype system (157). These results further emphasise the
complexity of serotype diversity among rotavirus strains and show that all serotypes identified
by each classification system for any of these strains should be considered in designing a
protective vaccine.
VP7. With a molecular weight of 34000, VP7 is the major constituent of the outer capsid as it
forms 30% of the total virion protein. Most neutralising antibodies in hyperimmune semm are

directed against the VP7 protein, which is encoded by the 7th, 8th, or 9th gene, depending on
the strain (73, 75, 76, 111). In addition, most rhesus rotavirus monoclonal antibodies which
precipitate VP7 neutralise rhesus rotavirus to high titre (75). Based on immune electron
microscopy evidence, the virus outer capsid is the site of attachment of these monoclonal
antibodies.
Isolation of VP7 monoclonal antibodies specific for human strains of serotypes 1, 2, 3
or 4 has made serotype identification of rotaviruses straightforward. Strains within a serotype
that are neutralised with different rates by serotype-specific monoclonal antibodies are called
"monotype" (33, 34). The term is analogous to "subtype" which is defined by polyclonal
antibodies.
Comparison of amino acid sequences of VP7 is a powerful tool for serotype
determination. Amino acid homology is very high within each serotype; however, sequence
conservation between strains of different serotypes is significantly less (69, 70). The
relationships found by sequence analysis among rotaviruses have correlated with those
obtained by neutralisation assays.
Amino acid sequences of rotavirus mutants resistant to neutralisation by VP7
monoclonal antibodies have been analysed to predict the major neutraUsation epitopes on VP7
(44, 107, 175). Each of the mutants analysed demonstrated a single amino acid substitution in
VP7, and these mutations occured only in specific variable regions VR5, VR7, or VR8. The
ability of a single monoclonal antibody to select for a mutation in either VP5 or VPS suggested
a close spatial relationship between these regions on the mature VP7 molecule.
Finally, the impact of glycosylation on the antigenicity of VP7 has been studied by the
amino acid replacement method (26, 44). A mutation made at position 211 of SAl 1 created a
new glycosylation site and rendered the mutant virus resistant to neutralisation by

hyperimmune antiserum. These results suggested that VR8 containing amino acid 211 forms an
immunodominant site and that the mutation makes it inaccessible to neutrahsing antibodies by
adding a new carbohydrate side chain. This region, therefore, seems to be the dominant
antigenic site on VP7; however, its dominance can not be generahsed to the whole vims and
the role of VP4 in neutralisation described earlier should also be taken to account.

1.7. Natural Immunity:
The function of systemic and local immunity against rotaviral diarrhea has been
elucidated by different animal studies (102, 125, 161). Overall, these studies have shown that
the presence of serum antibodies is not itself a protective factor and antibody in the lumen of
the small intestine is an important determinant of protection against rotavirus infection. Also,
the protective role of passively acquired gastrointestinal rotavirus antibodies against rotavirus
illness has been demonstrated by similar studies (125).
Despite these findings, other mechanisms may also be involved in rotavirus immunity.
For instance, serotype-specific immunity has been shown in some animals but not in others
(19, 125). Also, an avirulent strain has provided protection against a non-related virulent
rotavirus infection (24), suggesting the possible function of such mechanisms as cytotoxic T
lymphocytes in immunity to the disease.
Homotypic immunity in humans mediated by VP7 and VP4 antibodies is induced
following the first rotavirus infection. Each outer capsid protein plays a function in resistance
to illness (88, 124, 187), and antibodies to neutralisation epitopes on these antigens can be
induced following infection with an attenuated vaccine strain (158).
Finally, the partial protection against rotavirus infection conferred by breast-feeding
during infancy should be mentioned. An example of this protection was shown by comparing
infection between breast-fed neonates and bottle-fed ones (28). The first group developed

fewer rotavirus infection than the second. However, the effect of breast-feeding on the
occurence of gastroentritis requires more studies, as the data presently available are limited.

^nt of Vaccines Against
The purpose of a rotavirus vaccine is to prevent severe rotavirus gastroenteritis during
the first 2 years of life when the disease is most serious (18). Local intestinal immunity
provides the most significant resistance to rotavirus disease. Studies in animals show that the
efficacy of a rotavirus vaccine partially depends on its potential to induce intestinal IgA
antibodies and other types of local immunity. Since infection of the local site seems to be the
most efficient means to stimulate local immunity, most efforts in experimental rotavirus
immunoprophylaxis have been and continue to be concentrated on the development of live
attenuated virus vaccines which can be given orally.

II. 1. Developing Rotavirus Immunity: Essential Problems:
In developing an efficient strategy for rotavirus immunoprophylaxis, a number of
questions should be answered. First, it should be clear how effective homotypic immunity is in
preventing reinfection and disease. Although reinfection within the first few years of life
seems to be common in certain conditions, it is not clear if the reinfecting virus usually
represents a different serotype. The assessment of the extent and duration of homotypic
immunity requires longitudinal surveillance of infants and children to identify the serotype of
different isolates and clinical details of each illness associated with rotavirus infection. A
comparison between children neonatally infected by rotavirus and those who did not experience
such an infection showed that homotypic immunity is relatively effective in protecting against
diarrheal disease (17); infected children experienced almost 50% fewer rotavirus diarrheal
episodes during the next 3 years than non-infected individuals. Also, severe diarrheal disease

after reinfection was not observed in the first group, whereas some individuals from the second
group developed severe symptoms.
The second question includes the protective efficacy of attenuated rotavirus mutants.
Rotavirus infection occurs primarily in the epithelium of the small intestine. In such infections,
attenuation is associated with a diminished immune response (27). Therefore, a delicate balance
must be established between acceptable attenuation and satisfactory immunogenicity. Again,
the study of children infected at birth showed that although these neonatal infections were
attenuated, they could induce immunity against rotavirus diarrhea for at least 3 years (17). Thus
an attenuated infection can be protective.
How to induce heterotypic immunity and or how many serotypes to include in a
rotavirus vaccine to provide maximum protection are other questions that must be answered.
Although there are at least four human serotypes of rotavirus which are epidemiologic ally
important, sufficient heterotypic immunity could probably be achieved by one or two serotypes
to protect against most rotavirus infections. This type of immunity has been shown between an
animal rotavirus and a human rotavirus. However, it remains to be determined if effective
heterotypic immunity can be induced in humans by infection with an animal rotavirus (193,
196).

II. 2. Strategies for Producing Rotavirus Vaccines (Non-adenovirus Systems):
Several strategies have been adopted in attempts to develop an efficient rotavirus
vaccine. Some of these methods are conventional, whereas others are based on novel
approaches using molecular biology. Although rotavirus vaccines produced by the
conventional means have, at least in some cases, shown protective efficacy, their variable
effectiveness in some other trials could have been due to challenging strains in nature. This
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problem, which seems to be common in some different viral and bacterial diseases, has lead to
the molecular-biology-based strategies for producing a live attenuated vaccine.
A. Cell Culture of Human & Animal Rotavirus Isolates:
Shared antigens found in human and animal rotaviruses have lead to the idea that the
Jennerian strategy for vaccination can be expanded to work against rotavirus infection. Due to
these common antigens, those infants and children who developed illness following rotavirus
infection established a serologic response not only to the infecting human strain but also to
various animal strains. This approach gave rise to promising results during animal studies in
which calves administered a bovine rotavirus in utero were protected from disease following
challenge at birth with a human rotavims of serotype 1 (97).
Many different animal studies have been carried out to evaluate reactogenicity and
efficacy of rotavirus strains in providing heterotypic immunity. Some of these studies have lead
to the establishment of vaccines with over 70% protective efficacy against any rotavirus
diarrhea, whereas others have shown a much lower rate of protection (185, 186). Meanwhile,
variability of protective efficacy in different trials in various places suggested that serotypespecific immunity in young children was not primed by previous rotavirus infection (187).
B. Virus Reassortant Isolation:
The segmented genomes of rotaviruses are able to undergo gene reassortment following
coinfection of different viruses. This ability forms the basis of an efficient approach to the
development of attenuated rotavirus vaccine strains. A series of virus reassortants has been
isolated from human- and animal-rotavirus-coinfected cultures followed by selection (using
monoclonal antibodies) for the gene segment coding for VP7 from the human rotavirus parent.
This procedure could isolate single human rotavirus gene substitution reassortants in which the
human rotavirus gene for VP7 of serotype 1, 2, or 3 was present on a background of 10 animal

rotavirus genes (118). As expected, these reassortants exhibited the neutralisation specificity of
the human rotavirus parent. More important, ressortants containing the VP7 of one serotype
and the VP4 of another serotype have been shown to provide protection against either rotavirus
(88, 124). Reassortment has enabled scientists to generate a quadrivalent vaccine consisting of
rotavirus serotypes 1, 2, 3, and 4 (131). However, the protective efficiency of the vaccine
remains to be improved, e.g. by modifying the quadrivalent to a pentavalent with a human
rotavirus VP4 (87).
The reassortment approach might also be useful in developing an attenuated vaccine by
replacing a gene from an animal rotavirus into a virulent human rotavirus strain. This method is
based on the observation that gene 3 (encoding VP3), 4 (VP4), 9 (VP7) or 10 (NS28, NSP4)
each functions independently in the virulence of a porcine rotavirus for its natural host (88a).
Therefore, incorporation of gene 3 of an animal rotavirus, for instance, with a background of
human rotavirus genes would help to attenuate a wild-type human rotavirus strain.
C. Synthetic Peptides:
Vaccination against rotavirus infection may also be achieved by using the nucleotide
sequence of VP7 to produce peptides corresponding to the major antigenic sites on this protein
(5). The amino acid sequence of these antigenic sites required for the peptide production can be
determined by different methods such as identification of epitopes in those mutants that resist
neutralisation by monoclonal antibodies. Synthetic peptides corresponding to the identified
antigenic sites are then evaluated for their suitability in immunoprophylaxis. Although their
effectiveness in stimulating an effective primary response is questionable, these synthetic
peptides might be able to initiate the immune response to a live attenuated virus vaccine (172).

D. Passive Immunisation:
Passive immunisation has shown its effectiveness in preventing rotavirus disease in
animals (9, 97). This has also been the case in infants and young children. Two examples are
oral administration of children with human gammaglobulin containing rotavirus antibodies (7)
and antibodies from cows immunised with human rotavirus (45), both of which provided
protection among children.
Passive immunisation is also achieved by using reassortant rotaviruses. Mouse dams
hyperimmunised with a reassortant rotavirus containing VP4 and VP7 antigens, each
originating from a different serotype, were able to confer passive protection to their progeny
against challenge with either serotype (124).
E. Rotavirus-like Particles:
Using appropriate expression systems, immunogenically-important subviral particles
can be produced which retain some of the characteristics of the native virus. These particles can
properly interact with other recombinant proteins, a process which enables them to mimic the
structure of the assembled virus (51, 174, 183). The rationale behind virus structure immitation
is that empty capsids can provide protection against rotavirus infection (160).
As an expression system, baculoviruses have been widely used to produce different
recombinant proteins including rotavirus capsid components (30, 106). The báculo virus vector
utilises a strong promoter to express high amount of proteins which are very similar to their
authentic counterparts (105). It also uses many of the protein modification, processing and
transport systems that occur in higher eukaryotic cells which may be important for the complete
function of the expressed protein.

Simultaneous expression of rotavirus VP6 and VP7 proteins by using baculovirus
vectors has produced spherical particles resembling double-shelled rotavirus. This similarity
resulting from the proper interaction of the two proteins demonstrates the potential utility of the
procedure in providing protection against rotavirus disease. The method can be aimed at
preparing chimeric particles containing serologically different VP7 proteins to investigate the
protective role of this antigen.
F. Recombinant Vaccinia as a Rotavirus Vaccine:
Vaccinia viruses. These viruses have been used as a vaccine strain since the late 1700s,
indicating the safety of this viral system (119). As the virus replicates in the cytoplasm of
eukaryotic cells, it is easy both to introduce foreign DNA and analyse its expression. Other
properties of vaccinia virus required for foreign gene transfer are the wide host range of the
virus and its ability to accommodate a large amount of external DNA. Although the requirement
for ongoing viral infection may limit synthesis of host's proteins and eventually destroy the
host cell (121), the vector system has found several applications in biotechnology (119).
Vaccinia virus is one of the recombinant vector systems employed to produce VP? in
cell culture (2). However, VP? expressed as an intracellular antigen induced low levels of
neutralising antibodies in rabbits (2), and in mice antibody levels were at, or below, the level
of detection even following secondary immunisation (4).
VP7sc. To overcome this problem, a novel form of VP? has been constructed. First,
based on the evidence that the N-terminus domain contributes to VP? retention in the ER (134,
190), the VP? signal peptide resident in this domain was substituted by the signal sequence
from influenza virus haemaglutinin (HA) to produce a secreted version of the antigen (16?).
Following the initial report for obtaining cell surface expression of a secreted Plasmodium
antigen by adding the C-terminus membrane anchor domain of the HA (99), transmembrane

anchor sequences from the HA were incorporated to the coding sequences of the secreted VP7
to construct a novel, chimeric protein called VP7sc (3). DNA manipulation techniques were
then used to produce recombinant vaccinia viruses carrying the chimeric DNA coding for
VP7sc. When mice were inoculated with these viruses, the level of rotavirus-specific
antibodies observed in their serum samples was > 100-fold above the level induced by wildtype VP7 (3).
The high-level antigenicity of the cell-surface-anchored VP7 has been attributed to its
easy accessibility to B cells. VP7 concentration on the cell surface has also been suggested to
facilitate multipoint binding between the antigen and an individual B cell, a process which may
activate the B cell with high efficiency.
The engineered version of VP7 was also able to stimulate T cells more effectively than
did the wild-type protein. Again, the increased ceU surface concentration of VP7 peptides may
improve their association with major histocompatibility class n, leading to high stimulation of
helper T ceUs.
The necessity of both interaction between VP7wi and other rotavirus proteins (42) and
calcium-binding activity of VP7 (41) seems to be a constraint for an expressed VP7 to elicit a
high-level immune response as trialed by several groups (1, 116). However, the enhanced
ability of the cell-surface-expressed protein to induce neutralising antibodies suggest the
potential of VP7sc to present its epitopes without a need to interact with other proteins (40).
Apparently, surface presentation of VP7sc molecules in an array on the one hand, and the
substitution of VP7-VP4/ VP6 interactions by VP7sc-cell membrane linkage on the other hand,
are involved in enhanced neutrahsation activity of the protein.
Based on the above-mentioned results, VP7sc is thought to be more effective in
protecting recipient animals against rotavirus-induced diarrhea than the wild-type VP7. This

point has been elucidated by inoculation of mice with vaccinia-rotavirus VP7sc recombinants
(1). In addition to the efficiency of this recombinant vaccine in preventing morbidity due to
rotavirus infection in mice, VP7sc with its high immunogenicity also resulted in improved
protection in rotavirus naive animals including the suckling offspring.
VP6sc. Similar modifications have been made in the VP6 structure to improve the
antigenicity of this inner capsid protein. VP6 is highly immunogenic (74) and, following
expression in eukaryotic cells, correctly processed into protein identical to its native structure
(48, 142). Moreover, the potential of the antigen to be used as a vaccine has been shown by its
expression in severe combined immunodeficiency (SCID) mice in which the protein improved
the ability of the animals to survive challenge against chronic rotavirus reinfection (37).
A leader sequence from influenza virus haemaglutinin and a membrane-anchored
domain from a mouse immunoglobulin gene were integrated into the SA-11 VP6 gene fragment
to generate a chimeric form of the protein (VP6sc) (143). Secretion and cell-surface display of
the chimeric product was shown by using vaccinia vims as a vector. Subsequently, mice were
inoculated with the recombinant vector. Rotavirus-specific antibodies produced in the
inoculated animals were at a level 10 times higher than that produced by vaccinia-mediated
delivery of wild-type, intracellular VP6. This result further emphasises the importance of cellsurface display of rotavirus antigens in obtaining high level protection.

II.3. Animal Models for Rotavirus Vaccine Trials:
Although the mechanism of immunity to rotavirus infection is poorly understood, the
infection and disease can be studied in different animals. The advantage of studying the
immune response to infection in an animal model is that the history of viral exposure is known
and can be controlled. Mice, rabbits and piglets are three major animals used for studies on
rotavirus disease and immunity, although the use of other animals including gnotobiotic lambs

(161) and calves (151) for this aim has also been reported. The level of antigenicity, protection
and possible hazards of native and recombinant viral particles produced for vaccine
development are frequentiy examined using these animals.
1, Mouse:
Mice have been used as suitable animal models to study the mechanisms involved in
rotavirus disease/immunity. Several strains of mouse rotavirus with ability to cause diarrhea in
infant mice have been isolated (102, 160). In addition, neonatal mice can develop severe
diarrhea following infection with human rotaviruses (127, 128, 182). Since mice are
susceptible to rotavirus disease during a short period of time after birth (192), protection
studies of rotavirus strains have been limited to neonatal animals (50, 104, 129, 160).
Meanwhile, adult animals need to be used for better understanding different types of protective
mechanisms. Based on the idea of occasional infection of older mice with rotavirus, an adult
mouse model has been developed to study mechanisms of immunity (188). In this system,
infection rather than illness was needed, protection resulting in diminished virus shedding
following challenge. Although homotypic immunity was induced in this model, no heterotypic
protection against reinfection was obtained.
2. Rabbit:
Rabbit rotaviruses have been isolated by several laboratories (155, 156, 179).
Rotavirus seems to be endemic in rabbit populations as suggested by the fact that most rabbits
possess antibody to rotavirus by two to three months of age (38, 39).
The animal model developed from the laboratory rabbit provides potential opportunities
in studying immunity to rotavirus (31, 79). Compared with many other animal models, the
rabbit shows several advantages including increased age of susceptibility, lower cost compared
with large animals, easy sample collection and manipulation due to the more convenient size of

the animal compared with mice. Also, like suckling mice (126), rabbits can receive antibodies
from their mothers via the placenta (31).
Compared with mice and piglets in which enzyme-linked immuno-sorbent assay
(ELISA), electron microscopy or fluorescent focus assays are used to monitor virus replication
(57, 164, 165, 181), virus infection in the rabbit model can be detected directly by plaque
assay of either intestinal contents or fecal samples (31). Despite detecting virus replication in
mice by plaque assay of intestinal contents, viral grow curves have not exceeded input (at
disease-producing dosages). Meanwhile, the rabbit system is less reliable for detection of
infection based on clinical symptoms which are difficult to interpret in rabbits (31).
A systemic evaluation of the immune response and duration of illness can be easily
addressed under given conditions in rabbits. Induction of complete homologous protection,
antibody responses to specific rotavirus proteins, and induction of neutrahzing antibodies have
been observed in the rabbit system. These observations have facilitated the study of the kinetics
and serotype specificity of the humoral immune response in rabbits (32). This study has been
aimed particularly at addressing whether homotypic or heterotypic immunity results from
primary rotavirus infection, an essential issue in the development of a rotavirus vaccine.
Despite the advantages of the rabbit model addressed above, the system suffers a major
disadvantage; maintaining animals under strict isolation is required for inoculation of
seronegative rabbits, an important step toward successful use of the rabbit for the study of
rotavirus infections.
3,

Piglet:
Newborn gnotobiotic pigs is another animal model used to study rotavirus infection. In

these animals, many feamres of rotavirus infection including onset of virus shedding, duration
of virus shedding, total yields of virus recovered, and development of immune response appear

to be similar to results reported for the mouse and rabbit models (31, 127, 164). In addition to
the immunogenicity of rotavirus VP4 and VP7, the role of antibodies to these antigens in
protecting against challenge with virulent parental rotavirus has been evaluated by using piglet
models (88). This study showed that infection with a reassortant rotavirus bearing VP4 and
VP7 neutralisation antigens derived from two viruses of different serotype induced immunity to
both parental viruses. In providing vaccines based on rotavirus reassortants, this finding might
be worthwhile although increased levels of humoral and mucosal antibodies would have
important roles in inducing heterotypic immunity (62).

Section IIL Adenoviruses: Efficient Vectors for Recombinant Rotavims
Vaccine Development
III.l. Adenoviruses: Properties Facilitating Gene Therapy & Vaccine
Construction
Adenoviruses have several important criteria which make them suitable for gene transfer
purposes. Firstly, there is no known association of human malignancies with adenoviral
infection (See Section III.6.4: Oncogenicity of Human Adenoviruses), a criterion that is not
entirely met by retroviruses. Secondly, the viral genome of linear double-stranded DNA can
accommodate foreign genes of up to 7-7.5 kilobases. Thirdly, host cell replication is not
required for the expression of the transferred foreign gene. As a result, nondividing or slowly
proliferating cells can be easily infected with adenoviruses. In fact, the slow rate of cell
turnover will be in favour of the adenoviral vector system if the chronicity (time period) of
expression depends primarily on cell turnover rather than on suppression or loss of the
exogenous gene (101). Fourthly, adenoviruses can be produced in high titres (with up to 10^
virions produced per infected cell), a critical requirement for in vivo somatic gene therapy.
Lastly, recombination events which may result in modification or inactivation of the foreign
gene are rare in this vector system (195). Considering all these properties, adenoviruses have

found widespread applications in gene therapy trials in vitro and in vivo (8, 22, 35, 59, 101,
108, 147, 148, 168).
In addition to general properties that make gene transfer applications of adenoviruses
straightforward, several other features add to their utility for recombinant vaccine construction.
Firstly, virions and viral genome produced in host cells remain stable for a substantial period of
time. Secondly, very high level expression is possible because most of the macromolecular
biosynthesis in adenovirus-infected cells is virus directed at late times after infection. In fact,
viral-infected cells remain intact for a long period of time before lysis, facilitating the collection
of virus and virus-specified intracellular proteins. Thirdly, proteins made in adenovirus-based
expression systems would be expected to have all the post-translational modifications that
might be critical for their functional and antigenic properties. Finally, Adenovirus-based
vaccines could be delivered orally, e.g. in enteric-coated capsules. Table 1 shows examples of
adenovirus application for recombinant vaccine development.

III.2. Adenovirus Genome: Structure & Function
Adenoviruses are medium-sized non-enveloped viruses containing a linear doublestranded DNA of 20-30 X 10^ kb molecular weight (71). The DNA which exists within nonenveloped, icosahedral capsids, contains short inverted terminal repeats (ITRs). Figure 1
shows a map of the human adenovirus type 5 (Ad5) genome. Based on the two-phasereplication cycle of the genome, viral DNA sequences are classified as early (E) regions and
late (L) regions. El (comprising ElA & ElB), E2, E3 and E4 are expressed during the early
phase of replication. Expression of the El A region is needed for efficient transcription of viral
early genes (86). ElB encodes proteins involved in viral DNA replication and viral and cellular
mRNA metabolism and protein synthesis during infection (68). E2 products function in viral
DNA replication (52, 144, 166, 184). E3 is probably involved in the control of the host
immune response to virus infections in vivo. (82, 85, 191). Proteins encoded by E4 region

probably play a role in viral DNA replication and improvement of the efficiency of late viral
gene expression (81, 153). Viral DNA requires both viral and cellular proteins for its
replication which initiates at either end of the genome.
Transcription, which begins following the initiation of DNA replication, is driven by
the major late promoter (MLP). The process terminates near the right end of the genome and its
products give rise to different mRNAs encoding most of structural proteins of the virus.
During production of these proteins at late times in permissive infections, host-cell protein
synthesis remains inactive and the cell's translation machinery synthesises specifically viral
proteins.

III.3. Human Adenoviruses: Expression Vectors:

Adenoviral vectors used as recombinant expression systems can be divided into 3
groups (66). Nondefective vectors contain insertions of foreign genes in the regions other than
El, mostly in the E3 region. Due to their ability to replicate in normal human cells,
nondefective adenovirus vectors have a great potential to be used as recombinant live viral
vaccines.
Different parts of E3 have been deleted to show that this region is not essential for viral
replication. Deletion of the 1.9 kbp Xbal fragment contained within this region, for example,
resulted in a virus that not only could replicate in cultured human cells but also showed growth
advantage over wild-type {wt) virus (15). The insertion of a variety of foreign genes into the
adenoviral genome (Figure 2) has been made using the Xbal site at the 79.4 to 84.7 map unit
(m.u) deletion as a cloning site. It has also been known that vectors desirable for high level
expression are those with inserts in the E3 parallel orientation. Apparently with such insertions,
mRNA transcripts originate either from the E3 promoter or from the MLP.
Helper-independent-defective vectors are the second Ad-based vector systems that do
not need a helper virus for their replication but can replicate only in specialised cells that

provide important functions in trans (78). In fact, all these vectors have been designed to
replicate in 293 cells that express the El region of Ad5 and complement the replication of El"
Ad2 and Ad5 mutants (See below). These vectors can, therefore, be easily propagated in 293
cells even if they have foreign sequences inserted into their El region. To extend the capacity
of helper-independent vectors, developing cells derived from 293 cells that express additional
parts of the adenovirus genome would be worthwhile.
The deletion of different portions of the El region may be beneficial for therapeutic
aims. For example, the expression of the early region A (ElA) is required for efficient
transcription of viral early genes which function in replication initiation (13, 14, 80).
Moreover, the ElA region in collaboration with other viral and cellular oncogenes, is able to
transform different cell types (139, 150). Therefore, the deletion of this genomic region not
only impairs the adenoviral lytic cycle in cells but also arrests the potential tumorigenicity of the
virus.
The ability of adenoviruses to shut off host cell protein synthesis may be undesirable
for high level expression of proteins used as diagnostic reagents or antigens, since it results in
cell death and terminates gene expression. Therefore, strategies for deletion of viral genes such
as portions of the EIB 58-kDa protein critical in host cell shut off might be useful for extension
of protein synthesis in vector-infected cells. Although these vectors could only be propagated
in 293 cells, they could infect many other human cell types for protein synthesis. So-achieved,
attenuation of viruses not only helps the production of proteins secreted into the medium but
also seems advantageous for vaccine development.
Helper-dependent vectors are based on the ability of a second virus to complement the
growth of the adenovirus in otherwise nonpermissive cells (98). Foreign inserts are usually
recued into a region near the middle of the Ad DNA molecule and downstream from the MLP
to give high level expression (66). These vectors have a high capacity (-35 kbp) to accept

foreign sequences and are, therefore, useful for cloning large DNA fragments. However, they
are not useful as vaccines due to the variability of helper/vector composition and the uncertain
efficiency of its expression in vivo. In addition, the efficiency of these expression vectors is
reduced as the host cell's synthetic machinery is partly devoted to replicating the helper virus.

IIL4. Adenovirus Propagation In 293 Cells:
293 cells are a special human embryonic kidney cell hne containing and expressing Ad5
El sequences. They provide trans-acting ElA proteins, compensating the replication deficiency
of ElA deleted adenoviruses (67). These cells are best suited for propagation of helperindependent-defective vectors. In general, the exogenous gene to be expressed is first inserted
into a subgenomic viral DNA fragment propagated in a bacterial plasmid. The resultant
construct is usually rescued into full-length infectious viral DNA by cotransfection into 293
cells with either a second viral DNA or a second plasmid, containing the rest of the viral
genome plus the overlapping sequences required for homologous recombination. Rescue can
also be achieved by in vitro ligation to reconstitute a complete viral DNA molecule prior to
transfection (78). Figure 2 shows typical strategies for rescue of either El insertions (above
map) or E3 insertions (below map) into the viral genome by cotransfection with restricted viral
DNA. Cleavage by restriction enzymes reduces the infectivity of the parental viral DNA. This
cleavage can also improve the efficiency of isolation of recombinant vectors resulting from in
vivo recombination.
The cell line used for virus propagation and the strategy adopted for the extraction of
viral DNA are two important factors affecting virus infectivity. Adenovirus infectivity is higher
with the 293 cell line than with many other human cells as DNA recipients (67). For this
reason, 293 cells are often used for transfection even if the viral recombinant contains an intact
El region. Also, purification procedures that retain the terminal protein which is normally
attached to the ends of viral DNA give rise to higher infectivity (150).

The desired viral recombinant is identified by plaque isolation and analysis of viral
DNA structure by restriction and gel electrophoresis. Although these methods are often
satisfactory, a background of nonrecombinant viruses sometimes demands screening
many plaque isolates before obtaining the desired recombinant. Backgrounds of
nonrecombinant viruses are obtained due to residual infectious parental virion DNA and
can be eliminated by the use of viral DNA propagated only in the form of bacterial
plasmids (65).
IIL5. Insertion Sites In the Adenovirus Genome
Two regions, El and E3, within the 36 kb Ad5 genome are frequently used to make
insertions or substitutions of DNA and produce helper-independent recombinant viruses
(figure 2). Despite the lack of requirement for El gene products for viral replication in
human 293 cells, two subregions within El must be retained to provide the vector with full
replication proficiency in this cell line. The first subregion which is important for virus
viability includes the left inverted terminal repeat (ITR) and packaging signals (180). The
second is a segment to the end of El encompassing the protein DC gene. Up to 3.2 kb of
the El region can be deleted without interfering with the ability of the virus to grow in the
293 cell line.
E3 is the second region of the Ad5 genome widely used for cloning foreign DNA.
Deletion of 2 kb can be made in E3, which allows insertion of between 4 and 5 kb of
foreign DNA and produces recombinant viruses with complete ability to replicate in any
permissive host cell. Combined deletion in the El and E3 regions would permit insertion
of ~8 kb of external DNA into vectors that will replicate in human 293 cells.

Table 1, Examples of Adenovirus-based Recombinant Vaccine
Development
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Figure 1. The Human Adenovirus Genome:
Viral DNA sequences are classified as early regions and late regions. The early
mRNAs (blue arrows) and late mRNAs (pink arrows) are designated E and L, respectively.
The polypeptides are designated by roman numerals for the virion structural proteins
and in kilodaltons for nonstructural virus-coded translation products. DBP: DNA-binding
protein; ITR: inverted terminal repeats; MLP: major late promoter. p-TP: the precursore
to the terminal protein (taken from G. W. Both's data with permission).
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Figure!, Helper-independent Adenovirus Vectors:
The method for rescue of foreign DNA into the Ad5 genome. The phenomenon
which occurs by In vivo recombination is shown for inserts in the early region 1 (El)
(above map) and in the early region 3 (E3) (below^ map). Solid lines indicate Ad5
sequences and open lines indicate foreign DNA fragments. Bacterial plasmid
[ e.g. pXCXa for E l region (Xu; unpubHshed) and pFGdXl for E3 region (78)]
sequences are shown by dashed lines. Restriction enzymes required for rescue
of the external DNA into either region are also shown.

III.6. Adenovirus-based Recombinant Vaccines: Advantages & Disadvantages:
1. Safety & Efficacy
Adenoviruses, particularly Ad4 and Ad7, have been used as unattenuated vaccines in
military recruits for several years to prevent epidemics of respiratory disease (64). Their
application for more than 20 years has had no major complications attributable to these
vaccines. The safety, immunogenicity and efficacy of these vaccines are well-known so that
they were licensed in 1980 for oral administration to military personnel (145). Meanwhile,
their pathogenic and oncogenic potential (See below) has outweighed any necessity for
adenovirus vaccines in the general population.
Prior exposure of adenoviruses is another potential problem for their use as vaccines. A
majority of the human population has been infected, often in childhood, with one or more
adenovirus types especially Ad5. Immunisation of very young children using adenovirus-based
vaccines seems a reasonable solution.
Following the vaccines being delivered orally, in enteric-coated capsules, the viruses
replicate in the gut and induce immunity against respiratory infections caused by different
serotypes of adenoviruses. The antiviral immunity in the respiratory tract probably includes the
mucosal immune system which has mucosal epithelia as the first line of defence against entry
of many different pathogens into the body. Indeed, oral immunisation used for adenoviral
vaccine delivery seems to be the most effective route for obtaining mucosal immunity. This is
because the early precursors of B and T lymphocytes contained within the gastrointestinal tract
can migrate selectively to distant mucosal sites where they express their immunological effector
functions, mostly the production of secretory IgA. Therefore, following oral immunisation,
antigens of other pathogens expressed by the adenovirus vectors may induce immunity at
distant mucosal surface against the relevant pathogens (64).

2. Human Ad5: A Potential Vaccine Vector:
Infection with Ad5, compared with other viral types such as Ad7, generally does not
result in serious complications, although such complications are more frequent in young
children. Based on studies of antibody titres to Ad5 in different geographic regions, from 50%
to almost 100% of the population over the age of 5 years have been infected with Ad5 (64).
Regarding the natural infection of many millions of people and the fact that there has been no
significant mortality linked to Ad5, even the unattenuated form of Ad5 would be a safe vector.
Despite the ability of Ad5 to cause persistent infection in the host and its potential reactivation
under suitable conditions, e.g. in immunocompromised individuals (80), it is not obvious that
the general application of adenoviruses as vaccines would increase complications resulting
from virus reactivation in these individuals.
3. Function of E3 In Viral Infection:
The highly conserved nature of most Ad E3-encoded proteins among different human
serotypes suggests their important role in virus persistence within human individuals. For
instance, a 19-kD glycoprotein, gp 19 kD, binds to major histocompatibility complex (MHC)
class I antigens and prevents their transport to the surface of the cells infected by the virus.
Consequently, cytotoxic T lymphocytes will be unable to identify viral peptides normally
presented as complexes with MHC class I antigens. The activity of E3 gp 19 kD will thus
interfere with cell lysis by T cells (66). A 14.7 kD protein is a second E3 protein that functions
to protect Ad-infected cells from tumor necrosis factor, sensitivity to which is induced by El Aencoded proteins.
The activities of E3 proteins suggest that one of their main roles would be to inhibit
clearance of the virus from the infected host and establish persistent infection. Despite the high
sensitivity of 293 cells to the E3 gpl9k-mediated down-regulation of class I expression on the

infected cell surface, it has been shown that most human cells are resistant to this effect (149).
Meanwhile, a subpopulation of human cells might be susceptible to this regulation and might,
therefore, remain resistant to T-cell mediated lysis. Such a ceU group would be able to provide
a reservoir of virus protected from the immune system and result in persistence without
widespread distribution of infectious virus within the infected host.
The role of E3 functions in regulation of the immune response to infection seems to be
more complex than is currently understood and its significance to the human situation is still
unclear. On the other hand, E3" vectors might show superiority as vaccines compared with
vectors with E3 functions, even though limited knowledge about E3 activities is available.
Infectious recombinant adenovirus vectors with deletion in E3 functions might be unable to
cause compHcations by establishing latency or persistence in the vaccinated host. However, all
observations related to these activities should be taken into account in the design of Ad vectors
as human vaccines, particularly because of the altered pathogenicity that has been observed
with E3" vector in a cotton rat model (56).
4. Oncogenicity of Human Adenoviruses:

The oncogenic feature of adenoviruses is one of the major problems that may limit their
applications as recombinant vaccines. The ability of these viruses to induce tumors in
experimental animals or to transform cells in culture (180) is attributed to El sequences which
are involved in regulation of viral and cellular gene expression. In fact, all adenoviruses
examined have proved their ability to transform cells in culture, and some have been shown to
induce tumors in rodents following virus injection into these animals. However, subgroup C
adenoviruses including Ad5, which is widely used as a vector for foreign DNA, have shown
very low or no oncogenic potential in animals (86).

Potential tumorigenicity of adenoviruses would be a major problem considering their
possible worldwide use as vaccines, particularly in infants where they might otherwise be most
efficient. Despite this fact, for a number of reasons, these viruses are unlikely to be oncogenic
in humans. Firstly, there has been no naturally occurring tumor in any animal shown to result
from adenoviruses (72). Secondly, human adenoviruses show low effectivenesss for inducing
tumors or transforming cells in culture and for both of these functions millions of viral particles
per transforming event would be needed. Thirdly, as shown in cell culture assays,
adenoviruses normally replicate in, and lyse, cells from their natural host, and only transform
nonpermissive cells. Human cells transformed by human adenoviruses have been produced
only with difficulty by DNA-mediated transforming techniques and only by using noninfectious viral DNA sequences. In fact, no human cell transformed by infectious adenovirus
has been developed as a permanent cell line.

III.7. Application of Adenoviruses For Rotavirus Vaccine Development
In order to examine the potential of adenovirus/rotavirus recombinants for protection
against rotavirus infection, the VP7sc sequence of rotavirus strain SAl 1 was inserted into the
adenovirus E3 region. The expression of VPTsc and its cell-surface display was evaluated
using several recombinant Ad5 viruses which were similar with respect to the insertion site
(E3) but different regarding the configuration of the VPVsc gene (20). Viruses with the gene
inserted in the left to right direction expressed considerable levels of VPTsc. These expression
levels could be monitored even at early times during infection regardless of whether or not an
SV40 promoter and polyadenylation signal flanked the gene. The insertion of the gene in the
right to left orientation, however, gave rise to no detectable VPVsc even when the gene was
coupled with an SV40 promoter. These results both show the ineffectiveness of SV40
promoter for VPTsc expression and further emphasise the high expression of the inserts
oriented in parallel with E3 (See Section in.3: Human Adenoviruses: Expression Vectors).

Although Ad5/VP7-infected 293 cells produced a small form of VP7sc (41 kDa) that
stayed in the ER for a period of time, they also expressed a larger VP7sc molecule (45 KDa)
which was displayed on the cell surface membrane, as detected by immunoprecipitation (20).
Furthermore, some uncharacterised changes were observed in the VP7sc produced in the 293
cell line. These post-translational modifications occurred in post-ER compartment and were
suggested to be specific to this cell line.
The recombinant vector Ad5/7.4 lacking flanking SV40 sequences showed the highest
level of expression of VP7sc in tissue culture. This virus was, therefore, tested to see if it
stimulated an immune response in female mice which had a protective effect in pups challenged
with the homologous rotavirus.
In agreement with the results obtained using vaccinia virus as the vector (1), immunity
achieved by administering the human Ad5/7.4 recombinant to dams could be transferred to the
suckling offspring. The results were even more encouraging than those achieved by vaccinia
virus. While lower protection was obtained using a single dose of vaccinia virus compared
with two doses of the same virus, complete protection against diarrhea was observed when
even a single dose of Ad5/VP7sc was administered. In fact, the adenovirus recombinant
produced higher serum antibody titre than did the vaccinia recombinant so that the second
vaccine dose seemed to be unnecessary.
Despite the high protection achieved by Ad5A^P7sc and recombinant vaccinia virus, the
nature of this protection is not fully understood. This is particularly the case when offspring
receive this protective immunity from their parents. Although anti-rotavirus serum antibodies
induced by the single expressed antigen were at an easily detectable level, in milk antibody
levels were too low to be detected (20). However, rotavirus-hyperimmunised mice have
produced much higher antibody levels, demonstrating a correlation between protection and
level of neutralising antibodies in milk (126). Meanwhile, the presence of other protective but

unknown agents in milk should also be taken into account. In summary, the magnitude of the
immune response seems important, the best protection being obtained when the serum and
milk antibodies are at their highest level, even if the measured antibodies may not necessarily
be responsible for protection.

Section I. Recombinant DNA Preparation
The components of the reagents used in this section are detailed in Appendix L

1.1. Agarose Gel Electrophoresis (AGE):
A Biorad Gel Electrophoresis Apparatus was used to perform agarose gel
electrophoresis. All the gels used for DNA preparation/analysis consisted of 1% agarose/trisborate (TBE) and all were run between 85-90V. Lambda DNA restricted with Hindlll and
A47C (134) restricted with Hinfi were used as molecular weight markers. DNA mixmres were
dissolved in DNA loading buffer prior to loading. Agarose gels were stained in ethidium
bromide solution.

1.2. Restriction Enzymes & Buffers:
All the restriction enzymes and their relevant buffers (as 10 x stock solutions) as well as
T4 DNA ligase and ligation buffer were purchased from Boehringer & Mannheim.

1.3. DNA Purification By NAGS Golumn:
DNA sample was diluted in 4 volumes of 0.625M NaCl/TE buffer. The mix was
heated first at 70°C and then at 45°C each for 10 min. A NACS PREP AC mini-culomn
(GIBCO BRL) was used to purify the VP7sc fragment. The column was first equlibrated with
3x 1ml of 2M NaCyTE and 3 x 1ml of 0.5M NaCl/TE pre-warmed at 45°C was used to wash
the column. DNA pre-warmed at 45°C was loaded into the column by a Pasteur pipet. The
column was then washed 3 x 1ml 0.5M NaCVTE pre-warmed at 45°C. DNA elution was
performed by 3 x 100|il of 2M NaCl/TE and the eluted DNA was collected to an eppendorf
tube . 300|il H2O, l|il tRNA and 1ml of cold 96% ethanol were added to the DNA solution
and the mix was left on dry ice (-70°C) for 30 min. DNA was pelletted by centrifugation at

15000 g for 15 min. at 4°C. The pellet was then washed with 70% ethanol, air-dried, and
dissolved in 10|il H2O.

1.4. Preparation of Competent Cells:
Escherichia coli strain JM109 was grown in sterile Luria-Broth (LB) medium 0/N. 500
ml LB was inoculated with 2ml 0/N culture and grown to OD 0.8 (3-4hrs). The culture was
chilled on ice for 30 sec. and centrifuged at 4000 ^ for 15 Min at room temperature (RT)
(Beckman, JA-14 rotor). The pellet was resuspended in 500ml sterile chilled 10% glycerol.
Centrifugation was repeated and the pellet was dissolved in 20ml chilled 10% glycerol. 50^1
ahquots were made and freezed on dry ice/ethanol and finally stored at - 70°C.

1.5. Bacterial Electrotransformation:
Each ligation mix was added to 200|LI1 competent cells. The cells were subjected to
electroporation at L8kV by using a Biorad E. coli Pulser. The electroporated cells were
incubated in 1ml SOC solution supplemented with glucose and MgS04 and agitated at 37°C
for Ihr. Bacteria were grown at 37°C on ampicillin (50 |ig/ml) agar plates containing 100|il
isopropylthio-P-D-galactoside (IPTG) solution and 20|LI1 of 50|ig/ml 5-bromo-4-chloro-3indolyl-P-D-galactoside (X-gal).

1.6. Plasmid DNA Extraction:
1.6.1. Small-Scale Plasmid Preparation:
Colonies suspected to be recombinant were picked and inoculated into glass tubes each
containing 2ml LB medium/50|Lig/ml ampicillin. The inoculates were grown at 37°C 0/N by
agitation. Next day, cell pellets were prepared by centrifugation of the cultures, dissolved in
lysozyme solution and incubated at 0°C for 15 Min. After addition of alkaline-sodium dodecyl
sulphate (alkaline-SDS) solution, the samples were cooled on ice for 5 Min. High-salt solution

was added and the cooling step was repeated for 30 Min. The potassium-SDS precipitate was
spun down by centrifugation at 15000 g for 10 Min at 4°C (2K15; Sigma). Equal volume of
phenol: chloroform solution was used to extract each DNA followed by 3 Min. centrifugation
at 3000 ^/RT. The supernatant was transferred to a fresh tube and mixed with an equal volume
of 4M ammonium acetate pH 7.2. DNA was then pelletted by adding cold 96% ethanol,
cooling the sample on dry ice 0/N and spinning at 15000 ^ for 10 Min. at 4°C. The pellet was
then washed with 70% ethanol, air dried at RT and dissolved in H2O.
1.6.2. Medium-scale Plasmid Preparation:
The culture from one of the positive bacterial clones was spread over an Am;?
(100|ig/ml) plate and incubated at 37°c 0/N to produce single colonies. One of these colonies
was inoculated into a 2ml

LB/Amp

glass test tube and incubated ~8hrs at 37°C on a shaking

incubator. 0.1ml of the culture was then added to 100ml

LB/Amp

in a sterile flask and

incubated 0/N at 37 °C by agitation.
The 0/N culture was centrifuged in a 250 ml plastic centrifuge bottle at 3000 ^ for 10
Min at 4°C (Beckman JA-14). The cell pellet obtained from centrifugation was subjected to the
procedure used for medium-scale plasmid DNA preparation as per QIAGEN Manual:
1) The bacterial pellet was dissolved in 4 ml of buffer PI and incubated for 5 Min at RT after
addition of 1ml buffer P2.
2) The sample was mixed with 4 ml of chilled buffer P3 and incubated on ice for 15 Min.
3) Bacterial pellet was discarded from the supernatant after 30 Min centrifugation at 15000 g/
4°C (Beckman JA-20).
4) A QIAGEN-tip 100 was equilibrated by addition of 4ml QBT buffer to the column, which
was allowed to empty by gravity flow.
5) The supernatant was appHed to the column and allowed to empty by gravity flow.

6) After washing the column with 2x 10ml buffer QC, the DNA was eluted by using 5ml
buffer QF.
7) 0.7 volume of isopropyl alcohol was used to precipitate DNA. The mixture was immediately
centrifuged at 9500 g for 30 Mmin at 4°C. The DNA pellet was washed with cold 70% ethanol,
air-dried, and dissolved in 150|il H2O.

1.6.3. Large-scale Plasmid Preparation:
The positive bacterial sample was spread on an ampicillin agar plate containing IPTG
and X-gal and incubated at 37°C O/N to generate single white colonies. A number of colonies
grown O/N was incubated in a test tube containing 1ml LB by agitation at 37°C for 6 h. The
cultures were then transferred to 500 mm comical flasks containing 250 ml sterile LB medium
and incubated by agitation at 37°C O/N. The overnight cultures were spun down in plastic
tubes and by centrifugation at 3000 g for 10 Min at 4°C (Beckman JA-14). Large-scale plasmid
DNA was prepared as per QIAGEN Manual:
1) The bacterial pellet was dissolved in 10 ml of buffer PI and incubated for 5 Min at RT after
addition of 1ml buffer P2.
2) The sample was mixed with 10 ml of buffer P3 and incubated on ice for 20 Min.
3) Bacterial pellet was discarded from the supernatant after 30 Min centrifugation at 15000
^/4°C (Beckman JA-20).
4) A QIAGEN-tip 500 was equilibrated by addition of 10 ml QBT buffer to the column, which
was allowed to empty by gravity flow.
5) The supernatant was applied to the column and allowed to empty by gravity flow.
6) After washing the column with 2 x 30 ml buffer QC, the DNA was eluted by using 15 ml
buffer QF.

7) 0.7 volume of isopropyl alcohol was used to precipitate DNA. The mixture was immediately
centrifuged at 9500 g for 30 Min at 4°C. The DNA pellet was washed with cold 70% ethanol,
air-dried, and dissolved in 250 |il H2O.

1.7. Measurement of DNA Concentration:
The concentration of plasmid DNA was measured at 260 nm and 280 nm by using a
UV spectrophotometer (DMS-90).

1.8. PGR Amplification Reaction:
PGR reaction was carried out in a 0.5ml eppendorf tube using a Gorbett FTS-1 Thermal
Sequencer. The components of the reaction mixture together with their volumes and
concentrations are shown in Table 2.
Following addition of reagents to a sterile tube, 50ILI1 paraffin was overlayed and the
solution was spun briefly. Table 3 shows the cycles applied for PGR amplification.

1.9. Purification of PGR Product:
The amplified DNA was purified as following: 50 |il ether was added to the PGR
product and mixed by vortexing. The supernatant including ether and paraffin was removed
after 30 sec centrifugation of the sample at RT. The total volume of the sample was increased to
100|Lil by adding H2O. DNA was extracted by phenolxhloroform solution. The mixture was
briefly spun to precipitate the extracting solution plus protein molecules. The supernatant was
mixed with 100|il of 4M ammonium acetate and precipitated using cold 96% ethanol. DNA
pellet achieved by 15 Min centrifugation at 15000 ^/4°G was dissolved in 10|a.l H2O. 400|il TE
buffer plus 250|il of 0.5M NaGl were added to the DNA and the mix was heated at 70°G for 10
Min. NAGS column was washed with 3 x 1ml of 2M NaGl/TE and equilibrated with 3 x 1ml
of 0.2M NaGl. The DNA was loaded onto the column by a Pasteur pipet. The column was then

washed 3 x 1ml of 0.2M NaCl/TE. DNA elution was performed with 3 x 100|il of IM
NaCl/TE and the sample was collected in an eppendorf tube. The eluted DNA was mixed with
10 [ig tRNA and 2 volumes of cold 96% ethanol and then cooled on dry ice for 20 Min. It was
then spun down at 15000 ^ for 15 Min at 4° C and washed with 70% ethanol. The DNA pellet
was dried at RT and dissolved in 10|LI1 H2O.
* *

Table 2, The Polymerase Chain Reaction (PCR) Mix
Reagent

Volume

Sterile H20

36.95 |Lil

lOx Amplification
buffer n (including
MgCl2)

5.0|il

Ix

dN'l'P mix*

6.0^il

2.5 mM of each dNTP

5' primer

1.0|dl

0.2 mM

3' primer

0.5|il

O.lmM

Taq DNA polymerase

0.5II1

2.5 Units/ 50|il

DNA template

0.05^il

0.05|ig/ 50|il

* dNTP mix included: dATP, dCTP, dGTP, and dTTP.

Final Concentration

Table 3. PCR

Amplification Cycles:

Step

Temperature

Time

Step 1.1
1.2
1.3
Step 2.1
2.2
2.3
Step 3.1
3.2
3.3
Step 4.1

91
61
72
91
61
72
91
61
72
4

IMin
IMin
2Min
45 sec
IMin
2Min
45 sec
IMin
7Min
50 Min

No. of Cycles
xl cycle

x21 cycles

xl cycle

Section II. Cell Transfection
The components of the reagents used in this section and section EI are detailed in Appendix n.
11.1. Passage of 293 Cells:
The stock of 293 cells frozen in sterile tube at -70°C (or liquid nitrogen) was thawed at
RT and cells were allowed to recover and grow for 4-5 days. The medium was removed from
the flask and cells were rinsed 2 times with ~1 x citric saline. All but a trace of citric saline
(enough to cover the cell monolayer) was removed and the dishes were left for 10 Min until
cells started to round up and lift off. They were then resuspended in 1 x Minimal Essential
Medium F11 (MEMFl 1; GIBCO BRL) growth medium pre-warmed at 37°C and distributed to
new dishes. The cells were diluted 1:2 or 1:3 for 150-mm dishes (Coming) and 1:5 for 60-mm
dishes (Coming). Cells in new dishes were incubated at 37°C and split once they became 8090% confluent.
11.2. DNA Transfection:
A number of 60-mm dishes containing 293 cells at 70-80% confluence were set up for
transfection. Different combinations of pXCVP7, pJM17 and carrier DNAs were prepared in
microfuge tubes each containing 500)11 HEBS solution (See Table 7 in Results). 2.5M CaCl2
(50 mg/ml) was added to each tube and mixed well before incubation at RT for 15-30 Min. The
suspension in each tube was added to a separate dish without removing the growth medium
and incubated at RT for 4.5 h. The medium was removed and the agar overlay prepared
beforehand was added (10 ml/dish). The plates were incubated at 37°C for 7-10 days for
plaques or cytopathic effect (CPE) to appear.

II.3.

Screening Adenovirus Plaque Isolates:

II.3.1.Screening

Plaques:

Well-isolated plaques were picked from the transfected cultures by punching out agar
plugs using a sterile Pasteur pipette. The crushed agar was transferred to a sterile microfuge
tube containing 1ml phosphate buffered saline (PBS^+) + 10% glycerol. The isolated plaques
were frozen on dry ice and thawed at RT. The tubes containing virus plaques were subjected to
ultrasonication on ice for 7-10 Min. Sonication following the freezing-thawing process was
repeated 3 times. The plaques were spun at 15000 ^ for 10 Min at 4°C The supernatant was
transferred to a fresh tube and stored at -70°C until use.
11.3.2. Cell Infection:
For each isolated plaque, a 60 mm dish of 293 cells was set up and prepared for use
when the cells reached 80-90% confluence. The medium was removed from 293 cell dishes
and 200|il of the solution containing virus plaques was added. The virus was distributed over
the cell monolayer and adsorbed at RT for 30 Min. After virus adsorption by cells, 5 ml
MEMFll + 250|il heat-inactivated horse serum (HS) was added to each dish followed by
incubation of cells at 37°C. The cytopathic effect (CPE) was visible after 2 days and complete
after 4 days.
11.3.3. Analysis of Viral DNA:
After completion of CPE, the infected cells were manipulated as follows:
A.

The dishes were left undisturbed in the tissue culture hood for 30 Min. The medium

was then removed gendy by suction.
B.

0.5 ml pronase was added to each 60 mm dish to digest the cells at 37°C for 3-4 h.

C.

The viscous lysate was added to a 1.5 ml eppendorf tube.

D. The DNA was extracted by using 0.5ml phenol xhloroform solution. The lysate was
centrifuged to precipitate cell debris and proteins.
E. 50|LI1 of 30% sodium acetate was added to the extracted DNA followed by precipitation
with 1ml of cold 96% ethanol. The DNA pellet was obtained by centrifugation at 15000 g for
10Minat4°C.
F. The pellet was washed first with 96% and then with 70% ethanol.
G. After drying at RT, the DNA peUet was redissolved in 50|il of 0.1 x SSC.
H. Viral DNA was digested with Hindlll 0/N and analysed by 1% agarose gel
electrophoresis.
11.4. Preparation of Virus Stock:
200|LI1 of each virus, i.e the virus identified as recombinant, the wildtype adenovirus,
and the adenovirus produced by infection of cells with the pFG140 plasmid, was used to infect
60 mm dishes containing 293 cells with 80-90% confluence. After adsorption of the added
virus by the cells, 5ml MEMFl 1 + 100|LI1 HS was added to each dish. The infected cells were
incubated at 37°C for 48 h for CPE to appear. The cells with complete CPE were harvested by
scraping them off the plastic surface using a sterile cell lifter (Costar) and collected in an
eppendorf tube to obtain a cell pellet by centrifugation. Each cell pellet obtained from an
individual dish was resuspended in 1ml PBS^^ + 100ml glycerol. Virus was released by
breaking infected cells with freezing and thawing and subsequent sonication for 10 Min. The
virus stock solution was then stored at -70°C until use.
11.5. Titration:
A. 60mm dishes of 293 cells were set up and used when the cells reached 80-90%
confluence.
B.

Serial 10-fold dilutions of the virus were prepared starting from 0.2ml vims stock.

C. The medium was removed from the dishes and 0.2 ml of each virus was added to each
dish. Cells were infected by 30-60 Min incubation at RT and occasional tipping of the dishes.
D. 10ml overlay prepared beforehand and equilibrated in a 44°C waterbath was added to
each dish and incubated at 37°C for 4-5 days for CPE to appear.
E. Plaques appearing in each dish were counted to calculate the plaque forming unit (PFU)
for each virus stock.
II.6. Detection of Protein Expression:
A. 293 cells which were grown to 90-80% confluence in 60 mm dishes were infected
with the recombinant adenovirus samples, pFGMO plasmid as a negative control, and
recombinant El~ adenovirus containing the EW VPVsc gene {Ad5 EWVPVsc) as a positive
control, at a multiplicity of infection (MOI) of 20 PFU/ cell. The infected cells were incubated
in MEMFl 1 + 5% HS at 37°C.
B. At 18 h, and 24 h postinfection, the medium was removed from the dishes and the
cells were washed with 5ml PBS^" prewarmed at 37°C. Then, 5 ml MEMFl 1 met" was
added and the cells were left for Ih at RT. 3ml of the added MEMFllmet" medium was
removed and 5|J.l [^^S]methionine (1150Ci/ mM; ICN Radiochemicals) was used for
labelling the protein for 2 h at 37°C.
C. Cells were washed with 2 x 5 ml ice cold PBS^". 1ml cold PBS^- was added and the
cells were scraped off the dish and transferred to an eppendorf tube. Cell pellet obtained by 2
min centrifugation of cells at RT was dissolved in 100}il lysis buffer + l|il approtinin
(Img/ml). After vortexing, cells were disrupted by sonication at 0°C for 7 Min. 900|il of
dilution buffer was added and the cell debris was removed by 3 min centrifugation at RT. 2|LX1
of the corresponding antiserum (anti-RV4 for WaVP7sc and anti- D35 for £WVP7sc) was
added to the supernatant and left at 4°C 0/N.

D.
30|il of a 1:1 suspension of protein A sepharose beads was added to each tube and
mixed by rocking for 2 h at RT. Beads were spun down and the supernatant was removed. The
precipitated beads were washed with 3x 1ml IP wash buffer and 1 x 1 ml final wash buffer.
E.
50|il 1% SDS/25mM Tris pH 7.4 was added to the washed beads and boiled at
100°c for 5 Min. The beads were centrifuged at RT for 2 Min and the supernatant was
transferred to a fresh eppendorf tube.
F.
5|il of the sample was mixed with 2|il loading buffer and analysed on a 12%
polyacrylamide gel run at 125 V for 2hrs. Rainbow™ [^^C]methylated protein molecular
weight marker (Amersham) was used as marker. The gel was rinsed with H2O and left on the
fixer solution by shaking for 30 Min. It was rinsed with H2O and rocked in amplify solution
(Amersham) for 15 Min by shaking at RT. The Amplify was removed and the gel was rinsed,
blotted and dried using a slab gel dryer (SE 1160; Hoefer) for 1 h at 80°C. The proteins were
detected by autoradiography.

Section III. Sequencing Reaction
The standard procedure described below (154) was used for sequencing promoter
DNA. The reagents used for the reaction were purchased as a sequencing kit from Phaimacia.

III.l. Denaturation of DNA Template:
2|ig of DNA per sample was denatured with 2|il of 2M NaOH in a total volume of 10|il
in an eppendorf tube at RT for 10 Min. One third of a volume of 3M sodium acetate and 3
volumes of 96% ethanol were added to precipitate the denatured DNA. DNA pellet was
obtained by 10 Min minutes centrifugation at 15000 g/4°C' washed with 70% ethanol, air-dried
and dissolved in 10|al distilled water. The denatured DNA was stored at -20°C until use.

111.2. Annealing Reaction:
For each sample, 10|il denatured DNA was mixed with 2|uil annealing buffer and 2|nl
primer. The mix was heated at 65°C for 2 Min and cooled slowly for 30 Min.

111.3. Sequencing Reaction:
Four eppendorf tubes were marked as A, T, C and G for adenine, thymine, cytosine
and guanine, respectively. 2.5|il of each dideoxyribonucleotide (ddNTP) was added to the
corresponding tube. The T7 DNA polymerase was diluted in the enzyme dilution buffer so that
1.5U enzyme in 2|il volume was used for each sequencing reaction. The diluted enzyme was
added to an eppendorf tube containing 0.5|il of a-32p dATP (3000 Ci/ mmole; ICN), 1.5|il
sterile water and 3|J.l of labelling mix A (Pharmacia).

111.4. Labelling Reaction:
6|il of the enzyme-label mix prepared above was added to each denatured/ annealed
DNA sample and incubated at RT for 5 Min. 4.5|J,1 of the mix was then added to each ddNTP
tube and incubated at 37°C for 5 Min.

111.5. Termination Reaction:
5jil of stop solution (Pharmacia) was added to each labelling reaction and the samples
were heated at 80°C for 2 Min prior to loading.

111.6. Polyacrylamide Gel Electrophoresis:
2|LI1 of each sample was loaded onto a 6% polyacrylamide gel and run 30-35 min
mA/120V. After electrophoresis, the gel was fixed first in 15% acetic acid and then in 15%
ethanol. It was then dried in a gel drier for 45 Min. The exposure of the gel was made by
autoradiography.

Section I. Recombinant DNA Preparation:
1.1. pBVP7 Plasmid Construction:
The original plasmid pJCWaVPTsc (Lockett, Xu & Both, unpublished) was digested
by Xhol and Sail to release the VP7sc gene from the rest of the plasmid. First, the plasmid was
digested by Sail in an appropriate restriction enzyme (RE) buffer at 37°C 0/N. Since there is an
X/z(9l-recognition site in the VP7sc fragment, the 5'a/I-cleaved plasmid was digested partially
with Xhol for 5, 10, 15, and 20 minutes to obtain the 1.5 kb fragment which includes the
VP7sc segment plus the SV40 polyadenylation signal. 1|LL1 of 0.5M EDTA was added to stop
the reaction. As shown in Figure 3, 5-10 minutes digestion was appropriate to release the
fragment. Therefore, the 10-minute sample was selected. The fragment was cut from the gel
and recovered by NACS column as described in Materials and Methods.
Bluescript (Ml3+) vector was digested with Xhol enzyme for 3 h at 37°C. The enzyme
was inactivated by heating of the mix. The digested DNA was loaded on the gel to detect the 3
kb digested Bluescript.
X/zoI-digested pBluescript (vector) and the purified VP7sc fragment (insert) were
mixed in an eppendorf tube containing T4 DNA ligase and ligation buffer. A second tube
containing all the components except VP7sc DNA, and a third tube containing Bluescript vector
DNA and hgation buffer were set up as negative controls. All the mixes were incubated at 16°C
0/N to allow ligation to proceed.
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plasmid further digested
with Xhol for 5 Min (2),
10 Min (3), 15 Min (4) and
20 Min (5).
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Figure 3. Analysis of the pJCWaVPlsc Plasmid Partially Digested With Xhol
The plasmid was first digested with the Sail enzyme overnight.
It was then cut with Xhol in 5,10,15 and 20 minute digestion
times to separate the 1.5 kb fragment consisting of the VP7sc
gene cassette and SV40 polyadenylation signal.

E. coli cells were transformed by the ligation products and grown on LB medium
which contained ampicillin, IPTG and X-gal. White colonies which were likely to be
recombinants were analysed. The plasmid DNA extracted from these colonies were digested
with different enzymes to find the positive clone in which the VPVsc had been inserted
correctly into the vector. Digestion with Xho\ identified a positive clone which had Ikb
fragment as a part of the VP7sc sequence, in addition to 3kb (Bluescript vector) fragment. This
clone was then subjected to digestion with other enzymes to determine the orientation of the
insert in the vector. In either case, the expected fragments were obtained (Figure 4 & Table 4).
1.2. pBCVP7 Plasmid Construction:
PGR primers were designed in which Apal and Kpn\ recognition sites were placed in 3'
and 5' primers, respectively:
5'
3'

CATGGTACCTAGTCGACCAATTCTCAT 3'
kpni
TAT GGG CCC ATT AGC TTC TAG AGA TCT. 5'
Apai

The amplification of the CMV promoter sequence contained in plasmid pCEP4
(Stratagene) was performed in a total volume of 50 lil. The conditions shown in Tables 2 and
3 (See Materials & Methods) were applied to the PGR reaction.
Both pBVPV (vector) and CMV promoter DNA (insert) were digested with KpnUnd
Apal. Following digestion reactions, both DNA samples were heated 10 Min at 65°C. DNA
was recovered by the phenol: chloroform extraction and ethanol precipitation.
KpnVApal restricted insert and vector were ligated to each other using the method
described for VP7sc/Bluescript ligation ( See Section LI). A reaction mix containing pBVP7
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figt/r^ 4. Examination of The VPJsc DNA Orientation In the
The constructed pBVP7 plasmid was digested with different
restriction enzymes which recognise sites at the ends or inside
the VP7sc DNA insert. The relevant fragments produced in each
digestion case showed the accuracy of the
insert's orientation (See also Table 4).

pBVPJPlasmid

Table 4, Fragments achieved by digestion of the pBVP7 plasmid:

Digestion with Xho\ resulted in the release of the 1 kb VPVsc gene cassette. SaR with
its single recognition site only linearised the recombinant plasmid, but when applied together
with Xhol, it produced 3 different fragments including VPVsc cassette, SV40 poly A signal
and the pBluescript vector. EcoRN has two recognition sites, one inside the VPTsc gene
cassette and one in the bluescript sequence. It therefore digested the vector to generate two
fragments of 1.2 kb and 3.4 kb.

Digesting Enzymes

Fragments expected (kb)

Fragments generated

Xhol

1.0, 3.2

1.0, 3.2

SaR

4.5

4.5

XhoVSall

0.6, 1.1, 3.0

0.6, 1.0, 3.0

EcoRV

1.2, 3.4

1.2, 3.4

but lacking CMV promoter DNA was set up as a negative control. Following ligation, the
mixes were heated at 70°C for 10 Min. The ligation product was transformed into E.coli cells
which were then grown 0/N to produce colonies.
DNA was analysed with different restriction enzymes to identify positive clones. Each
digestion reaction produced the expected fragments, indicating the accuracy of insertion of
CMV sequence into the pBVP7 plasmid (Figure 5 & Table 5).

1.3. pXCVP7 plasmid Construction:
pXCX2 plasmid (163) contains the left-end 452 nucleotides of the adenovims type 5
(Ad5) genome. pXCX3 plasmid is basically the pXCX2 in which a polylinker including Xhal,
Kpnl, Spel, EcoRY, BgHl, Sail and Xhol sites has been inserted into the Xbal cleavage site
(Xu; unpublished). 2 |ig of pXCX3 DNA was digested first with Kpnl and then with EcoRY.
The DNA was extracted with phenol: chloroform solution and precipitated by cold 96%
ethanol. The DNA was extracted with phenol:chloroform solution, ethanol precipitated and
dissolved in H2O.
of pBCVP? plasmid was digested with Kpnl and Smal and analysed by gel
electrophoresis. The 2.4 kb VPVsc.CMV fragment was excised from the gel and purified by
NACS column . The purified VPTsc.CMV DNA was ligated with the pXCX3 plasmid vector
and transformed into E. coll
5|Lig

Plasmid DNA prepared from colonies were digested with Sail to identify positive
clones. These were confirmed by further digestion with EcoRHEcoRY, and EcoRHXhol
37°C. Figure 6 shows the results of digestion reactions. The products of all reactions
confirmed the correctness of the recombinant clones and of the orientation of the insert (Figure
6 & Table 6). An overview of the standard procedures (152) used for construction of the
recombinant pXCVP7 plasmid is shown in Figure 7.
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Figure 5. Analytical Gel Electrophoresis of The pBCVPV Plasmid
The constructed pBCVPY plasmid DNA was digested with different
restriction enzymes which recognise sites in the vector or inside
the insert. The digested DNA was loaded on a 1% agarose gel.
In each case, the expected fragments were obtained, indicating
the accuracy of the insertion (See also Table 5). Digestion with
SaU. revealed another SaZI-recognition site at the 5' end of the CMV
promoter. This site had been unintentionally introduced into the 5'
primer sequence prepared and used for PGR reaction of the promoter.

Table 5. Fragments

Digesting enzyme

Produced

By Digestion

Fragments expected (kb)

of the pBCVPJ

Plasmid

Fragments generated

Xhol

1.0, 4.4

1.0, 4.5

Saa

2.4, 3.0

2.3, 2.9

XhoVSall

1.0, 0.8, 0.5, 2.9

1.0, 0.8, 0.5, 3.0

EcoRY

1.0, 4.3

1.0, 4.4

KpnVApal

0.8, 4.5

0.8, 4.5

KpnVEco^

1.2, 1.3, 3.0

1.2, 1.3, 2.9

A B C D E

3.0
1.4
0.8

0.5

A. :^DNA Marker
B. Sail
C EcoRI/EcoRV
D. EcoRI/XhoI
E.A47C Marker

Figure 6. Analysis of The Recombinant pXCVPJ Plasmid:
Digestion of the plasmid DNA with Sail enzyme released the
2.4 kb C M V / V P 7 S C fragment. Double digestion with EcoRI/EcoRV
produced 1.8 kb and 1.0 kb fragment, whereas EcoBl/Xhol digestion
released 1.3 kb and 1.0 kb fragments as expected.

Table 6. Fragments Produced By Digestion of the pXCVP
Plasmid:

The recombinant vector was digested with three sets of enzymes: 1. Sail released the
2.4 kb CMVA^PTsc fragment; 2. EcoRVEcoRY produced 1.8 kb and 1.0 kb fragments; 3.
EcoRUXhol produced released 1.3 kb, 1.0 kb, and 0.5 kb fragments.

Digesting enzyme

Fragments expected (kb)

Fragments generated (kb)

Sail

2.4, 6.0

2.4, 5.9

EcoRUEcoRY

1.8, 1.0, 6.0

1.8, 1.0, 5.9

EcoRUXhol

1.3, 1.0, 0.5, 6.0

1.3, 1.0, 0.5, 5.9

Figure 7. An Overoieiv of the Strategies used For Construction of
Plasmid pXCVPJ:

The WaVP7sc fragment including VP7sc gene cassette and SV40
polyadenyiation signal was separated from pJCWaVP7sc and inserted into
the pBluscript. The CMV promoter sequence was prepared by PGR reaction
from pCEP4 and ligated upstream of VVaVP7sc fragment in the constructed
pBVP7 plasmid. The 2.4 kb fragment including the CMV promoter sequence
and \VaVP7sc was then inserted into pXCX3 to produce pXCVP.
The 1.5 kb fragment containing WaVP7sc gene cassette and
SV40 poly adenylation signal.
• • l

pBluescript sequences
PCEP4 sequences

mm

CMV promoter sequences
Adenovirus type 5 (Ad5) genome sequences
Sequences flanking Ad5 sequences in plasmid pXCX3
Sequences flanking WaVP7sc in plasmid pJCVVaVP7sc

•

Polycloning site

Red arrows indicate either PCR reaction (in the case of the CMV promoter)
or ligation between a vector and an insert.
Black arrows show the 5'—>3' direstion of DNA fragments.
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Section II, WaVPTsc Gene Transfer Into 293 Cell Line
II. 1. Cell Transfection & Plaque Formation:
The VP7sc gene in pXCVP7 plasmid is flanked by portions of the Ad5 genome. On the
other hand, plasmid pJM17 carries an insertion on the El region which makes it too large to
package (114). pXCVP? and pJMlT plasmids are able to undergo homologous recombination
to reconstitute an El- adenovirus genome. Figure 8 illustrates the strategy used for
cotransfection of these two plasmids into 293 cells. In order to determine the optimum
concentrations of the plasmid DNAs to produce the maximum number of plaques, different
combinations of the DNAs were used for cotransfection (Table 7). High number of plaques
were obtained with a low concentration of pXCVP7 and a relatively high concentration of
pJM17. (Figure 9). The number of plaques was reduced to 70% by a 3-fold increase in the
pXCVP7 concentration, and the 6 fold and 9 fold increase in the plasmid concentration resulted
in the reduction of plaques to 25% and 15%, respectively. Furthermore, a 50% decrease in
pJM17 plasmid concentration produced very few plaques.

11.2. Analysis of Adenovirus Plaques:
Plaques obtained from samples 1-7 (Table 7) were analysed by ^mdlll digestion and
gel electrophoresis. Plaques were almost 99% recombinant adenoviruses carrying the
WaVP7sc sequence as shown by the loss of "G" band and the appearence of an extra 5.8 kb
band overlapping with "B" band (Figure 10).

11.3. Protein Expression:
The expression of WaVP7sc protein by Ad WaVP7sc was examined at 18 and 24hrs
post-infection. Uninfected 293 cells and cells infected with another recombinant AdEWVP7sc
(Xu, unpublished) were used as negative and positive controls, respectively. Although the

pXCVP?

•r Carrier D N A

Calcium Phosphate Precipitation

Cells

Figures.

Schematic

Illustration of Cotransfection of

293 Cells.

Plasmids pXCVP7 and pJM17 were used for cotransfection of 293 cells.
PJM17 is an El-Ad5 plasmid which can rescue a foreign
DNA into the El region providing that its partner contains the
corresponding left-hand sequences of the adenovirus genome.
Pink colour represents Ad5 sequences. Dotted fragment in plasmid
pXCVPZ indicates the CMV promoter sequences, and empty
fragments represent the sequences flanking the Ad5 sequences
in pXCX3 plasmid (See Figure 7). Black fragment in pJM17
represents the extra
sequences preventing the plasmid from
being packaged in the host cell.

Table 7. Combinations of Plasmid DMAs Used for

Cotransfection,

Eight different combinations of plasmids pXCX3 and pJM17 (samples 1-8) were used
to contransfect 293 cells. The transfection process was mediated by salmon sperm DNA as a
carrier. Plasmids pJM17 alone (sample 9) and pFGUO alone (sample 10) were used as
negative control and positive control, respectively. The number of plaques achieved by each
sample is also shown.

Sample
7
DNA

10

8

DNA Concentration (fig)

Carrier
DNA

2.5

2.5

2.5

2.5

2.5

2.5

2.5

2.5

pXCVP?

1.0

3.0

6.0

9.0

1.0

1.0

3.0

9.0

pJM17

5.0

5.0

5.0

5.0

2.5

2.5

2.5

2.5

2.5

2.5
3.0

pFG140
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number
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Figure 9. The Relationship Between Cotransfecting pXCVPJ and pJM17
Plasmid DNA Concentrations and Plaque Number:
Green coluirms and pink columns show the number of plaques achieved with
high concentration (5.0ul) and low concentration (2.5id) of pJM17 DNA, respectively.
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Figure 10, Electrophoretic Analysis of Recombinant Adenovirus DNAs,
Carrying CMV/VP7sc Fragment, Digested with Hind-III:
Two recombinant virus DNAs, designated 1 and 2, were analysed by Hind-III digestion
overnight followed by agarose gel electrophoresis (A). A schematic figure (B) illustrates
the fragments appearing or disappearing in recombinants (the sites of these fragments
are indicated in one of the recombinants by green arrows) compared to those in Ad5
and plasmid pFGMO. Part (C) shows the DNA profile of wild-type and recombinant
adenoviruses, a: XDNA marker; b: A47C marker; p: plasmid pFG140.
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expression of EWVP7sc protein in 293 cells was detected successfully, Unexpectedly the
expression of Wa protein was not observed in these cells (Figure 11).

Section III.Why Was WaVPTsc Expression Not Observed?
To answer this question, two possibilities were examined. First, and as an alternative
method, the WaVPTsc gene cassette was amplified by PGR reaction to see whether the gene
exists in the recombinant adenovirus genome. Second, the correctness of the CMV promoter
DNA sequence was examined by sequencing reaction.
111.1. PGR Amplification of WaYFlsc Gene Gassette:
PGR primers were designed with the following sequences:
5'

AGG GGT GGA GTT AAG GAT GAA GAG

3'

3•

GGG GGA AGG TTG TGA AAT GGA AAT

5'

Plasmids pJGWaVp7sc and pXGVP7 as well as two recombinant adenovirus vectors
were used as templates for amplification of the 1 kb VP7sc gene cassette contained in each
plasmid. The conditions applied for the PGR reaction are shown in Tables 2 & 3 (See Materials
& Methods). As shown in Figure 12, the Ikb gene was detected in all DNA samples including
the recombinant Ad5 DNA. Also, DNA from wild-type adenovirus was used as a negative
control which failed to detect the 1 kb band (data not shown).
111.2. Sequencing of the CMV Promoter DNA:
The GMV promoter region from the pBGVPT plasmid was sequenced to determine
whether any mutation was present.
The following primers were prepared and used for sequencing:

Primer A
Primer B
Primer C

5'
5'
5'

AAT TAG GGG GTC ATT ACT TCA TAG
CAA TTA CGG GGT CAT TAG TTC ATA
TTC CTA CTT GGC AGT ACA TCT ACG

3'
3'
3'

Approximately, 99.8% of the sequence matched with the expected sequence. However,
nucleotide substitutions were observed in two different positions (Figure 13). One of these fell
within a repeat sequence present in the CMV promoter DNA.

Figure IL Polyacrylamide Gel Electrophoresis for Examination of WaVP7sc
Protein in 293 Cells
The expression of the protein was tested in three recombinant Ad5 designated 1, 2,
and 3 in 18 and 24 hours post-infection. The cells infected with Ad5 EWVPTsc plasmid
containing E\V VP7sc (Xu, unpublished) and uninfected cells were set up as positive and
negative control, respectively. As shown, the -38 kb EW VPTsc protein was expressed in
the positive controls, but the expression of the equivalent protein from Wa serotype was not
observed.
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Figure 12. PCR Amplification of the 1 kb WaVP7sc Fragment
The PCR reaction was made to detect the WaVP7sc gene cassette in: A. two
recombinant adenovirus DNA obtained by transfection of 293 cells with
PXCVP7 and pJM17 (lanes 2 and 3), B. pJCWaVPVsc (lane 4), and C.
pXCVPT (lane 5). Also, the wild-type Ad5 DNA was tested as negative
control (data not shown). Lanes 1 and 6 represent XDNA marker and A47C
marker, respectively.
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Figure 13. The Result of Sequencing CMV Promoter DNA from
plasmid pBCVPJ
-

Almost 99.8% of the results matched the actual sequence of the promoter.
However, the nucleotide number 166 was recognised as "C" rather than "T"
in the actual sequence. Also a G—>T replacement was observed in the
nucleotide number 736. The underlined sequences upstream of the
TATA Box are the repeated sequences found in the major immediate early
(IE) gene.

GTCGACCAAT TCTCATGTTT GACAGCTTAT CATCGCAGAT CCGGGCAACG

10

20
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40

50

TTGTTGCATT

60

GCTGCAGGCG CAGAACTGGT AGGTATGGAA GATCTATACA TTGAATCAAT ATTGGCAATT

-70

80

90

100

AGCCATATTA GTCATTGGTT ATATAGCATA AATCAATATT
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150

160

110
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G G C T j ifTGGC CATTGCATAC

^ 170

180

GTTGTATCTA TATCATAATA TGTACATTTA TATTGGCTCA TGTCCAATAT GACCGCCATG

190

230

240

TTGACATTGA TTATTGACTA GTTATTAATA GTAATCAATT ACGGGGTCAT

TAGTTCATAG

250

200

300

CCCATATATG GAGTTCCGCG TTACATAACT TACGGTAAAT GGCCCGCCTG

GCTGACCGCC
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290

310

260
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340

350

360

CAACGACCCC CGCCCATTGA CGTCAATAAT GACGTATGTT CCCATAGTAA CGCCAATAGG

370

410

420

GACTTTCCAT TGACGTCAAT GGGTGGAGTA TTTACGGTAA ACTGCCCACT

TGGCAGTACA
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390

450

400

460

470

480

TCAAGTGTAT CATATGCCAA GTCCGCCCCC TATTGACGTC AATGACGGTA AATGGCCCGC
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500
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520

530

540

CTGGCATTAT GCCCAGTACA TGACCTTACG GGACTTTCCT ACTTGGCAGT ACATCTACGT
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560

570

580

590

600

ATTAGTCGCT ATTACCATGG TGATGCGTTT TGGCAGTACA CCAATGGGCG TGGATAGCGG
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650
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TTTGACTCAC GGGGATTTCC AAGTCTCCAC CCCATTGACG TCAATGGGAG

TTTGTTTTGG
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690
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700

710

720

CACCAAAATC AACGcfikcTT TCCAAAATGT GTCGTAATAA CCCCGCCCCG TTGACGCAAA
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750
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TGGGCGGTAG GCGTGTACGG TGGGAGGTCT ATATAAGCAG

790
AGATCTCTAG AAGC
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800
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820

770

780

AGCTCGTTTA
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840

L Strategies for Rotavirus Vaccine Development:
As discussed in the introduction, two strategies have had the most important impact on
rotavirus vaccine development in recent years: construction of reassortant strains and
recombinant DNA techniques. In this work, the molecular approach has been the focus. The
strategy has been to construct a recombinant viral vector which could express a modified
VPVsc gene corresponding to different human serotypes. The first results were obtained for
SA-11 VP7sc, and justified the application of the methodology for expression of VP7 proteins
from all rotavirus serotypes, especially because of the high degree of homology present
between the amino acid sequences of different serotypes (77).
Adenovirus was chosen as the vector because of its ability to be delivered orally. The
high level protection achieved by E3- adenovirus mediated expression of SA-11 VP7sc in mice
(20) encouraged virologists to examine the efficiency of the vector in El--adenoviruses. The
expression of SA-11 VP7sc gene, rescued in the El region of Ad5 in 293 cells has been
observed previously (Xu, unpublished). The current study is based on the above observation
which suggested the possible expression of VP7sc from iheWa serotype.

IL Approach
II.l. Subcloning:
Since WaVP7sc protein has akeady been expressed following transfection of COS cells
by pJCWaVP7sc plasmid DNA (Lockett, Xu & Both; submitted for publication), the gene
from this plasmid was subcloned into pBluescript which has markers selectable in a nonrecombinant background. The CMV promoter prepared from pCEP4 plasmid via the PGR
reaction, was then subcloned upstream of the WaVP7sc in the pBluescript vector. The
WaVP7sc/CMV fragment was then inserted into pXCXS, a plasmid containing the left-end 452

nucleotides of the Ad5 genome and another 2.5kb of flanking sequence (163), to give rise to
pXCVP7.

11.2. Construction of El" Ad5:
The ability of Ad5 to rescue WaVPVsc gene into its El region was tested using two
plasmids as cotransfection partners: pJMlT and pXCVPT. The former plasmid has almost the
entire genome of Ad5 except El, plus some extra sequences which prevent the genome from
being packaged as wild-type Ad5 in the host cell; however, it can undergo homologous
recombination with almost any other plasmid including pXCVP? which contains the
corresponding left-hand sequences of Ad5 genome. The method which was applied here was
so effective that almost 99% of the adenovirus plaques produced by cotransfection and tested
by restriction analysis were recombinant. Moreover, the two plasmids were used in different
concentrations to evaluate their effect on the recombination event and the number of plaques
produced. As a result, dramatic changes were observed in plaque number by delicate changes
in concentrations; an increase in the pXCVP? concentration and a decrease in pJM17
concentration clearly reduced the number of recombinant plaques. The result indicated the
importance of the balance between the concentration of the two plasmids required to achieve
satisfactory plaque numbers. Infectivity of adenovirus can be influenced by the cell line used
for virus propagation. The appearance of the adenovirus cytopathic effect in a short period of
time observed in the current study and in studies elsewhere implies that adenovirus infectivity
is considerably high with 293 cells. Therefore, even for transfection with E1+ Ad5, the 293
cell Une is an appropriate option as recipient.
Whether the rescue of a gene into Ad5 El region is advantageous over the rescue into
E3 is not precisely defined and depends, partly, on its application. For instance, both regions
play a role in inducing immune response against adenoviral infection and, therefore, in the
cases where such a response is to be regulated, the impact of deletion of each region on such a

regulation should be evaluated. E3 produces a protein which can interfere with the clearance of
the virus from the host and facilitate persistent infection (66). However, deletion of El renders
the genome essentially inactive except for the promoter driving foreign gene expression. This
might give an opportunity for proteins such as VP7sc to be expressed persistently by El" Ad5
on the cell surface and to induce a specific response which can be highly effective following a
second round of immunisation. Compared to the persistent expression of El" Ad5, deletion of
E3 only produces acute, though high level, expression from a repHcation competent virus.
In terms of ability to replicate, deletion of El is not desirable as the vector will be
restricted to growth in 293 cells. However, in the absence of El, low level expression can be
induced by some cellular factors (162) together with adenovirus proteins such as DNA-binding
protein which is produced by the E2a region (86). Compared to El" Ad5, E3" vectors replicate
in most human cells in culture (78) and partly in animals (20).
Apart from the question of whether or not the replication of adenovirus vector is
important in designing recombinant vaccines including rotavirus vaccine, inserts in El could be
expressed in many cell types in addition to 293 cells and in the recipient host. These kinds of
vaccines would be able to prevent possible side effects resulting from viral infectivity.

II.3. Evaluation of WaVPTsc Gene Expression:
Although subcloning of WaVP7sc into pXCX3 was followed by successful rescue of
the gene into the Ad5 El region, the gene failed to express the protein in 293 cells. Possible
reasons behind this problem were examined. Firstly, This was not due to a problem with the
antiserum used for immunoprecipitation of the antigen as shown by expression of WaVp7sc in
COS cells (Lockett, Xu & Both; Submitted for publication). Secondly, the WaVP7sc gene
cassette was detected by PCR amplification of the sequence from pJCWaVP7sc, pXCVP7 and
two recombinant Ad5 DNAs obtained from transfected 293 cells, whereas it was not detected

by PGR amplificattion of wild-type Ad5 which was used as a negative control. The method
further indicated the accuracy of the gene rescued into the Ad5 genome. Finally, the CMV
promoter DNA was subjected to DNA sequence analysis. This was made to detect any
mutation existing in the promoter sequence. The result of sequencing reaction showed
nucleotide substitutions in two regions: nucleotides number 166 and 736. These changes may
have been introduced by the Taq DNA polymerase during PGR amplification of the GMV
promoter DNA. The second nucleotide, i.e number 736 resides in a sequence which is one of
the repeated sequences in the major immediate early (IE) region of the GMV DNA (178). IE
regions are part of the GMV gene from which the GMV promoter is derived. These regions
contain conserved elements in their repeated sequences. Since the above nucleotide is a part of
one of these conserved elements, the failure of 293 cells to express WaVp7sc protein might be
attributed to the mutation in this region of the promoter. However, no obvious explanation can
be given as to the mechanism by which this occurs as or the conserved elements contribute to
the regulatory function of the IE region is not well known.

III. Future of WaVpTsc Gene Expression:
In parallel with the work in this thesis, similar plasmids for SA-11 VP7sc recombinant
construction were produced and shown to function successfully. If construction of the Ad5
GMV WaVP7sc recombinant were to be repeated, the SA-11 gene could be directly substituted
with VP7sc from Wa serotype in a plasmid which is known to function. Like previous studies
which detected changes in SA-llVP7sc protein attributed to 293 cells (20), these effects can be
studied on VP7sc from Wa serotype. Also, the immunogenicity of the protein can be tested in
an appropriate animal model such as mice to evaluate its credibility to be considered for
rotavirus vaccine development in the future.
The complex mechanism of rotavirus immunogenicity necessitates multiple serotypes of
rotavirus to be examined. Go-expression of WaVP7sc gene and the VP7sc from SA-11 or from

other serotypes is one option. Deletion in both El and E3 regions of Ad5 genome would
provide an opportunity for this purpose. The method allows the host's immune system to
challenge against both serotypes following infection with either.
Another strategy for improvement of immunity against rotavirus may be to improve
local immunity. The choice of adenovirus vector which induces mucosal immunity is one step.
The second step, however, would be to induce protein molecules effective in mucosal
immunity. Of these molecules are cytokines such as interleukin-6 (IL-6) which can induce
immunoglobulin A (IgA) production by promoting differentiation or proliferation of plasma cell
precursors (141). On the other hand, secretion of IgA antibodies is a major determinant in
characterisation of immune responses at mucosal surfaces. Considering this fact, local
immunity against a rotavirus serotype such as Wa could be effectively induced by developing
vectors coexpressing WaVPTsc and IL-6.

IV. Summary:
Recombinant DNA methodology has opened the way to generate another important type
of rotavirus vaccine. This is a live attenuated vaccine based on the expression of rotavirus
antigens, especially VP7, in host cells. The credibility of the whole system in terms of
manipulation of VP7 gene and choice of vector/ promoter has been tested in vitro and in vivo.
Considering high protection achieved by VP7sc carried by the adenovims vector, it is now time
to broaden the application of the method to other antigens/serotypes. Specifically, it will be
valuable to employ adenovirus vectors to produce vaccines against different rotavirus serotypes
involved in human and animal diseases i.e to obtain heterotypic protection, by co-expression of
different serotypic proteins. The chance of providing cross-serotype protection may also be
enhanced by inserting the genes encoding proteins shared between different serotypes of
rotavirus to the same adenovirus genome. Finally, regarding the critical role of
immunoglobulin A (IgA) in mucosal immunity, a more efficient vaccine could be constructed
by developing vectors co-expressing rotavirus proteins and those cytokines inducing IgAproducing cells.
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Appendix I.

1. DNA Preparation/ Analysis:

1.1. Tris-borate (TBE) As Electrophoresis Buffer:

TBE Stock Solution (per litre):
5x:

Tris base

54 g

Boric acid

27.5 g

0.5M EDTA (pH 8.o)

20|LI1

TBE Working Solution:

0.5x : Tris-borate (Stock)
EDTA (pH 8.0)

0.045M
O.OOIM

1.2. DNA Loading Buffer:

6x:

Bromophenol Blue

0.25%

Xylene Cyanol FF

0.25%

Sucrose In MQ Water

40% (W/W)

1.3. 0.5M EDTA (pH 8.0):
Add 18.6g disodium ethylenediammetetra-acetate.2H20 to 80ml H2O. Stir vigorously
on a magnetic stirrer. Adjust the pH to 8.0 with NaOH (~20g of NaOH pellets). Dispense the
solution into eppendorf tubes and sterilise by autoclaving.

1.4. TE Buffer, pH 8.0:
Tris-HCl, pH 8.0
EDTA, pH 8.0

lOmM
ImM

1.5. Lysosyme Buffer (lOOmL):
Reagent
IM Tris-HCl, pH 8.0
IM Giocose
0.5M EDTA, pH 7.5

Volume
(mL)
2.5
5.0
2.0

1.6. Lysosyme Solution:
Dissolve 5mg/mL lysozyme in lysozyme buffer.

Final Concentration
(mM)
25
50
10

1.7. Alkaline-SDS Solution (lOOmL):
Reagent

Final Concentration

Volume
(mL)

10 N NaOH
20% SDS

0.2 N
1%

1.8. Phenol: Chloroform Solution (50mL):
Add 25 mL phenol to 25 mL of a 24:1 mixture of chloroform: isoamyl alcohol.
1.9. High Salt Solution:
3M sodium acetate, pH 4.8
1.10. SOB solution:
1 litre:
Reagent

Amount

Final Concentration

Tryptone (Difco)
Yeast extract
NaCl
KCl
MgS04

20g
5.og
0.5g
10ml
20ml

2%
0.5%
0.05%
250mM
IM

1.11. IM Glucose:
Dissolve 18g glucose in 90ml H20 and adjust the volume to lOOml. Filter sterilise
through a 0.22 filter.
1.12. SOC solution:
2ml IM glucose per 100ml SOB solution.
1.13. L-broth (LB) medium (per litre):
lOg Tryptone (Difco)
5g Yeast extract
lOg sodium chloride
1.14. L-agar:
Add 15g Difco Bacto agar to 1 litre L-broth and sterilise.

1.16. QIAGEN Buffers:

Buffer*

Composition/
Concentration

Storage

RNase

100|ig/ml

4°C

Tris/HCl

50mM

EDTApH 8.0

lOmM

NaOH

200mM

SDS

1%

P3

KAc pH 5.5

3.0M

4°C

QBT

NaCl

750mM

Room Temp.

MOPS

50mM

Ethanol pH 7.0

15%

Triton-X-100

0.15%

NaCl

l.OM

MOPS

50mM

Ethanol pH 7.0

15%

NaCl

1.25M

Tris/ HCl

50mM

Ethanol pH 8.5

15%

PI

P2

QC

QF

Room Temp.

Room Temp.

Room Temp.

* PI: Resuspension Buffer; P2: Lysis Buffer; P3: Neutralisation Buffer;
QBT: EquHibration Buffer; QC: Wash Buffer; QF: Elution Buffer

1.17. PGR:
Melting temperature (Tm) in PGR:
Tm= 69.3+ 0.41 (GG)- 650/L
L= length of primer

1.18. PGR Amplification Buffer:

lOx:
500mM

KGl

lOOmM

Tris-HGl, pH 8.3

15mM

MgGl2

0.1%

Gelatin

Appendix IL
1. Propagation and Titration of Adenoviruses
1.1. Cell lines:
assays.

293N35 suspension cultures were used for all DNA transfections, infections and plaque

1.2. Media:
Minimal Eagle's Medium Fll (MEMFll), supplemented with 10% heat-inactivated
fetal calf serum (PCS) and 2mM L-glutamine was used for cell passage and cell growth.The
PCS, however, was replaced by heat-inactivated horse serum where needed. MEMPll powder
package (GIBC Laboratories) was dissolved in H2O (1 package/litre for 1 x medium and 1
package/500ml for 2 x medium). 2.2 mg sodium bicarbonate and lOOU/ml penicillin and
100|ig/ml Streptomycin were added and the medium was sterilised by filtration using 0.22|im
millipore (Masterflex). Prior to use, it was supplemented with 2mM L-glutamine and either
10% fetal calf serum or 5% heat-inactivated horse serum.

1.3. Citric Saline for Cell Passage:
lOx:
50g KCl and 22g sodium citrate were dissolved in H2O with the final volume of 500
ml. The solution was sterilised by autoclaving and diluted to 1 x citric saline solutions with
H2O.

1.4. Phosphate Buffered Saline (PBS2+ & PBS^-):
Solution A: 80g NaCl, 2g KCl, lL5g Na2HP04, 2g KH2P04/ L of H20.
Solution B: Ig CaC12.2H20/ lOOmL H20
Solution C: Ig MgC12.6H20/ lOOmL H20
The three solutions were sterilised by autoclaving.
For IL of PBS2-: 880mL of H2O was mixed with 100 mL of solution A, and then lOmL of
solutions B and C was added. For IL of PBS^", 900 mL of H2O was mixed with lOOmL of
solution A.
1.5. Overlay for Plaque Assay & Transfection:
Solution A: 2xMEMFll
5% Yeast ExtractHS

100ml
2ml
10ml

Solution B: 1% Agarose-

100ml

Bring solutions A and B to 44°C in waterbath before and after mixing.

2. Adenovirus DNA Purification:
2.1. Pronase Buffer:
Stock Solution:

PronaseO.OIM Tris-HCl pH 7.5

50mg
10ml

Preincubate at 56°C for 15' and then incubate at 37°C for Ihr. Aliquot into microfuge
tubes and store at -20°C. Dilute the stock 10 times with O.OIM Tris-HCl, pH 7.5 for pronase
buffer.
Pronase Buffer (10ml):

Reagent

Amount

Final Concentration

Stock Solution

9.8ml

0.5mg/mL pronase

0.5M EDTA

0.2ml

O.OIM

SDS

15mg

0.5M

2.2. 30% Sodium Acetate Trihydrate:
Dissolve 4.08 g sodium acetate trihydrate in 80mL H20 and adjust the volume to lOOmL.

2.3. O.lx SSC:
20 X SSC: 175 g NaCl and 88 g sodium citrate dihydrate was diluted in 1 litre H2O and
autoclaved.

3. DNA Transfection:
3.1. HEBS:
5g/L N-2 hydroxyethyl-piperazine-N-2-ethanesulfonic acid (HEPES) + 8 g/L NaCl +
0.37 g/L KCl + 0.125 g/L Na2HP04.2H20 + Ig/L Glucose with final pH of 7.1.
HEBS solution was aliquoted into small lOOmL glass bottles, autoclaved and stored at
4°C until use.

3.2. Carrier DNA:
2 mg of commercially available salmon-sperm DNA was dissolved to a final
concentration of 10 |Lig/mL HEBS prior to use.

3.3. CaCl2 (2.5M):
13.5g of CaCl2.6H20 was dissolved in 20 mL of distilled H2O and sterilised by
passing through a 0.22 [im filter. The solution was then stored in 1 mL aliquots in microfuge
tubes at -20°C.

4. Titration & Calculation of Plaque Forming Units (PFU):
For the dilution of 1 in lO'^ which produces 36 plaques when 0.2mL is inoculated, the
virus titre is calculated as following:
Number of plaques produced by 1 ml virus stock (FPU/ml) = 36 x lO'^/ 0.2 = 1.8 x 10^
If the number of cells in each dish is estimated about 10^, the volume of the virus stock
sufficient to produce 20 PFU/cell will be as follow:
20 X 106/1.8 X 109 =-0.01 ml

5. Detection of Expression:
5.1. Lysis Buffer (200ml):

Reagent

Amount

Final Concentration

DOC

200 mg

1%

Triton

200 III

1%

NaCl

600 III 5M

0.15M

Tris pH 8.0

500 III

25mM

SDS

1 ml 10%

0.5%

Reagent

Amount

Final Concentration

NP40

1 ml

0.5%

DOC

1g

0.5%

EDTA

2.4ml0.5M 6mM

Tris pH 8.0

2ml IM

5.2. Dilution Buffer (10 mL):

lOmM

5.3. IP Wash Buffer (10 mL):
Reagent

Amount

Final Concentration

Triton
DOC
SDS
NaCl
EDTA
Tris pH 8.0

2ml

1%
1%
0.1%
0.15 M
5mM
25m

2g

ml 10%
6 ml 5M
2 ml 0.5M
5 ml IM
2

5.4. Final Wash Buffer (200mL):

Reagent

Amount

NaCl
5ml 5M
EDTA
2ml 0.5M
Tris pH 8.0 0.5ml IM

Final Concentration
0.25M
5mM
25mM

5.5. Loading buffer (lOmL):
Reagent

Amount

Final Concentration

Tris pH 6.3
Sucrose
SDS
EDTA
DTT
Bromophenol Blue

500 ILIIM pH 7.2

50mM
10%
10%
2mM
IM

Ig
Ig
80 |Lil 0.5M
1.54 g
Tiny amount

5.6. lOx Running buffer (1 litre)

Reagent

Amount

Tris Base
Glycine
SDS

29
144
10

5.7. Fixer (500mL):

Reagent

Volume (mL)

Acetic acid

50

Methanol

150

H20

300

6. Sequencing Gel Components:

Reagent

Amount

lOx TBE

4ml

40% Acrylamide

5ml

H20

18ml

Urea

16.8g

TEMED

55|il

10% Ammonium persulphate

215}il

